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non-prereactive complex 
(C) BChE-( +)-cocaine 
non-prereactive complex 
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(D) BChE-( +)-cocaine 
prereactive complex 
FIGURE 2 
U.S. Patent Dec. 8, 2015 Sheet 3 of 6 US 9,206,403 Bl 
(A) (B) 
FIGURE 3 
U.S. Patent Dec. 8, 2015 
(A) 
Sheet 4 of 6 
(B) 
FIGURE 4 
US 9,206,403 Bl 
(C) 
U.S. Patent Dec. 8, 2015 Sheet 5 of 6 US 9,206,403 Bl 
6 ----- ·------------------------
1-Dl ----------RMSD I • TSl(A328WN33 ----------D2 -------D3 
,.-.._ 
~ 5 
'-' 
Ci 
r:FJ 
(A) ~ 
..... 
" 
0 
.) 
Q) 
u § 2 
...... 
rn 
i5 1 
0 
0 200 400 600 800 1000 1200 
Simulation time (ps) 
7 
,.-.._ 6 
~ 
'-' 5 Ci 
r:FJ 
~ 4 
..... 
0 3 (B) Q) u § 2 
..... (fl 
i5 
0 
0 200 400 600 800 1000 1200 
Simulation time (ps) 
FIGURES 
U.S. Patent Dec. 8, 2015 Sheet 6 of 6 US 9,206,403 Bl 
7 
6 
~ 5 
r:::1 
lfJ 4 (A) ~ 
.... 3 0 
OJ 
~ 
"' 2 -~ 
r:::1 
1 
TS 1 (A199S/S287G/A328W /Y3 32G) 
0 
0 200 400 600 800 1 000 1200 1400 1600 
Simulation time (ps) 
FIGURE 6 
US 9,206,403 Bl 
1 
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GOVERNMENT INTEREST 
Subject matter described herein was made with govern-
ment support under Grant Number R01DA013930 awarded 
25 
30 
by the National Institute on Drug Abuse (NIDA) of the 
National Institutes of Health (NIH). The government has 35 
certain rights in the described subject matter. 
40 
FIELD OF THE INVENTION 
The present invention relates to butyrylcholinesterase vari-
ant polypeptides, and in particular, butyrylcholinesterase 
45 
mutants having amino acid substitutions. 
BACKGROUND OF THE INVENTION 50 
Cocaine abuse is a major medical and public health prob-
lem that continues to defY treatment. The disastrous medical 
and social consequences of cocaine addiction, such as violent 55 
crime, loss in individual productivity, illness and death, have 
made the development of an effective pharmacological treat-
ment a high priority. However, cocaine mediates its reinforc-
ing and toxic effects by blocking neurotransmitter reuptake 
and the classical pharmacodynamic approach has failed to 60 
yield small-molecule receptor antagonists due to the difficul-
ties inherent in blocking a blocker. An alternative to receptor-
based approaches is to interfere with the delivery of cocaine 
to its receptors and accelerate its metabolism in the body. 
The dominant pathway for cocaine metabolism in primates 65 
is butyrylcholinesterase (BChE)-catalyzed hydrolysis at the 
benzoyl ester group (Scheme 1). 
2 
Scheme 1. 
Schematic representation ofBChE-catalyzed 
hydrolysis at the benzoyl ester group. 
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Scheme 1. Schematic representation of BChE-catalyzed 
hydrolysis at the benzoyl ester group. 
Only 5% of the cocaine is deactivated through oxidation by 
the liver microsomal cytochrome P450 system. Cocaine 
hydrolysis at benzoyl ester group yields ecgonine methyl 
ester, whereas the oxidation produces norcocaine. The 
metabolite ecgonine methyl ester is a biologically inactive 
metabolite, whereas the metabolite norcocaine is hepatotoxic 
and a local anesthetic. BChE is synthesized in the liver and 
widely distributed in the body, including plasma, brain, and 
lung. Extensive experimental studies in animals and humans 
demonstrate that enhancement ofBChE activity by adminis-
tration of exogenous enzyme substantially decreases cocaine 
half-life. 
US 9,206,403 Bl 
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Enhancement of cocaine metabolism by administration of 
BChE has been recognized to be a promising pharmacoki-
netic approach for treatment of cocaine abuse and depen-
dence. However, the catalytic activity of this plasma enzyme 
is three orders-of-magnitude lower against the naturally 
occurring (-)-cocaine than that against the biologically inac-
tive (+)-cocaine enantiomer. (+)-cocaine can be cleared from 
plasma in seconds and prior to partitioning into the central 
nervous system (CNS), whereas (-)-cocaine has a plasma 
half-life of approximately 45-90 minutes, long enough for 10 
manifestation of the CNS effects which peak in minutes. 
Hence, BChE mutants with high activity against (-)-cocaine 
are highly desired for use in humans. Although some BChE 
mutants with increased catalytic activity over wild-type 15 
BChE have previously been generated, there exists a need for 
mutant BChE with even higher catalytic activity. Thus, prior 
mutants provide limited enhancement in catalytic activity 
over wild-type BChE. 
Previous studies such as (a) Masson, P.; Legrand, P.; Bar- 20 
tels, C. F.; Froment, M-T.; Schopfer, L. M.; Lockridge, 0. 
Biochemistry 1997, 36, 2266 (b) Masson, P.; Xie, W., Fro-
ment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lock-
ridge, 0. Biochim. Biophys. Acta 1999, 1433, 281, (c) Xie, 
25 
W.; Altamirano, C. V.; Bartels, C. F.; Speirs, R. J.; Cashman, 
4 
residues hindering the structural changes, providing initial 
clues for the rational design ofBChE mutants with improved 
catalytic activity for (-)-cocaine. 
Previous molecular dynamics (MD) simulations of prere-
active BChE-cocaine binding were limited to wild-type 
BChE. Even for the non-prereactive BChE-cocaine complex, 
only one mutant (A328W/Y332A) BChE binding with (-)-
cocaine was simulated and its catalytic activity for (-)-co-
caine was reported by Sun et a!. No MD simulation was 
performed on any prereactive enzyme-substrate complex for 
(-)- or (+)-cocaine binding with a mutant BChE. In addition, 
all previous computational studies of Sun et a! and Zhan eta! 
ofBChE interacting with cocaine were performed based on a 
homology model of BChE when three-dimensional (3D) 
X-ray crystal structure was not available for BChE, as taught 
by Nicolet, Y.; Lockridge, 0.; Masson, P.; Fontecilla-Camps, 
J. C.; Nachon, F. J. Biol. Chern. 2003,278,41141 (hereinafter 
"Nicolet eta!"), recently reported 3D X-ray crystal structures 
of BChE. As expected, the structure of BChE is similar to a 
previously published theoretical model of this enzyme and to 
the structure of acetylcholinesterase. 
The main difference between the experimentally deter-
mined BChE structure and its model was found at the acyl 
binding pocket (acyl loop) that is significantly bigger than 
expected. It is unclear whether the structural difference at the 
acyl binding pocket significantly affect BChE binding with 
(-)-cocaine and (+)-cocaine. Although previous MD simula-
J. R.; Lockridge, 0. Mol. Pharmacal. 1999, 55, 83, (d) Duy-
sen, E. G.; Bartels, C. F.; Lockridge, 0. J. Pharmacal. Exp. 
Ther. 2002, 302, 751, (e) Nachon, F.; Nicolet, Y.; Viguie, N.; 
Masson, P.; Fontecilla-Camps, J. C.; Lockridge, 0. Eur. J. 
Biochem. 2002, 269, 630, (f) Zhan, C.-G.; Landry, D. W. J. 
Phys. Chern. A 2001, 105, 1296; Berkman, C. E.; Underiner, 
G. E.; Cashman, J. R. Biochem. Pharmcol. 1997, 54, 1261; 
(g) Sun, H.; Yazal, J. E.; Lockridge, 0.; Schopfer, L. M.; 
Brimijoin, S.; Pang, Y.-P. J. Biol. Chern. 2001, 276, 9330, (h) 
Sun, H.; Sherr, M. L.; Pang, Y. P.; Lockridge, 0.; Brimijoin, S. 
30 tions of cocaine binding with wild-type BChE and the reac-
tion coordinate calculations point to some amino acid resi-
dues that might need to be mutated for the purpose of 
improving the catalytic activity for (-)-cocaine hydrolysis, it 
remained unknown which exact amino acid mutations will 
35 result in a BChE with a higher catalytic activity for (-)-
J. Pharmacal. Exp. Ther. 2002,302,710, (i) Sun, H.; Pang, Y. 
P.; Lockridge, 0.; Brimijoin, S. Mol. Pharmacal. 2002, 62, 
220 (hereinafter "Sun eta!"); and G) Zhan, C.-G.; Zheng, F.; 40 
Landry, D. W. J. Am. Chern. Soc. 2003, 125,2462 (hereinafter 
"Zhan eta!"), herein all incorporated by reference, suggested 
that, for both (-)-cocaine and (+)-cocaine, the BChE-sub-
strate binding involves two different types of complexes: 
45 
non-prereactive and prereactive BChE-substrate complexes. 
Whereas the non-prereactive BChE-cocaine complexes were 
first reported by Sun et a!, Zhan et a! were the first reporting 
the prereactive BChE-cocaine complexes and reaction coor-
dinate calculations, disclosed in Zhan et a!. 50 
cocame. 
Computational studies of wild-type BChE and cocaine 
from Sun, et a!, based on a "homology model," suggest that 
the rate-determining step for BChE-catalyzed hydrolysis of 
cocaine is the rotation of the cocaine in the active site of 
BChE. By decreasing the hindrance of the rotation, the rate of 
the hydrolysis may be enhanced. Sun, eta! describes creating 
an A328W/Y332A BChE mutant by: (1) replacing Tyr332 
with Ala, "to reduce the steric hindrance and the Jt-Jt interac-
tion that impede rotation," and (2) replacing Ala328 with Trp 
"to provide a cation-Jt interaction to restore substrate affinity 
lost in disabling the Jt-Jt interaction." 
Sun et a! studied the A328W /Y332A BChE mutant using 
enzyme assays and kinetics. In vitro studies were conducted 
using human plasma and in vivo studies were conducted 
using male Sprague-Dawley rats. The mutant was found to 
have enhanced catalytic properties. The mutant was further 
55 studied using molecular modeling. The three dimensional (3D) structure of A328W/Y332A was generated from the 
computationally generated 3D model of wild-type BChE and 
changing the relevant residues using commercially available 
software. Cocaine was docked to the catalytic gorge of the 
It was demonstrated that (-)/(+)-cocaine first slides down 
the substrate-binding gorge to bind to W82 and stands verti-
cally in the gorge between D70 and W82 (non-prereactive 
complex) and then rotates to a position in the catalytic site 
within a favorable distance for nucleophilic attack and 
hydrolysis by S198 (prereactive complex). In the prereactive 
complex, cocaine lies horizontally at the bottom of the gorge. 
The main structural difference between the BChE-(-)-co-
caine complexes and the corresponding BChE-( +)-cocaine 
complexes exists in the relative position of the cocaine methyl 
ester group. Reaction coordinate calculations revealed that 
the rate-determining step of BChE-catalyzed hydrolysis of 
(+)-cocaine is the chemical reaction process, whereas for 
(-)-cocaine the change from the non-prereactive complex to 
the prereactive complex is rate determining. A further analy- 65 
sis of the structural changes from the non-prereactive com-
plex to the prereactive complex reveals specific amino acid 
60 mutant BChE using other commercially available software. 
The cocaine-enzyme complex was refined by molecular 
dynamic simulation. The data generated by the molecular 
modeling studies were consistent with enzyme assays and 
kinetic data. 
It should be noted that all prior computational techniques 
(molecular docking and molecular dynamics simulation) 
used by other researchers are based on an empirical force field 
US 9,206,403 Bl 
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which cannot be used to perform any necessary reaction 
coordinate calculation for the detailed nnderstanding of the 
complicated catalytic reaction process. As it is well-known, it 
is particularly challenging to model and simulate the detailed 
reaction pathway and predict the kinetics of such an enzy-
matic reaction. 
U.S. Patent Application Publication Nos. 2004/0121970; 
2004/0120939; and 2003/0153062, describe 20+BChE 
mutants, or "variants," from human and other animals, each 
having from one to six amino acid alterations and increased 
cocaine hydrolysis activity. For example, mutants include 
F227 A/A328W; F227 A/S287G/A328W; A119S/S287G/ 
A328W; A328W N332M/S287G/F227 A, A199S/F227 A/S/ 
287G/A328W and A119S/F227A/S287G/A328WN332M. 
The mutants have varying increases in catalytic activity, up to 
100-fold increase relative to wild-type BChE. 
There exists a need in the art for determining which pro-
posed mutant BChEs should have ever increasing catalytic 
activity and for generating those mutants which should have 
enhanced catalytic activity. 
SUMMARY OF THE INVENTION 
The present invention includes five novel human BChE 
mutants that have unexpected increased catalytic efficiency 
for cocaine hydrolysis. The mutants have various unique 
amino acid residue substitutions which provide the surprising 
enhanced catalytic activity. These mutants are (1) A199S/ 
A328WN332G mutant (SEQ ID NO: 2), which has a 
approximately 65-fold improved catalytic efficiency against 
(-)-cocaine; (2) A199S/F227A/A328WN332G mutant 
(SEQ ID NO: 8), which has an approximately 148-fold 
improved catalytic efficiency against (-)-cocaine; (3) A199S/ 
S287G/A328WN332G mutant (SEQ ID NO: 14), which has 
an approximately 456-fold improved catalytic efficiency 
against (-)-cocaine; ( 4) A199S/F227 A/S287G/ A328W I 
Y332G mutant (SEQ ID NO: 20), which has an approxi-
mately 1,003-fold improved catalytic efficiency against (-)-
cocaine; and (5) A199S/F227A/S287G/A328W/E441D 
mutant (SEQ ID NO: 26), which has an approximately 445-
fold improved catalytic efficiency against (-)-cocaine. 
6 
tive amonnt to lower the patient's cocaine blood concentra-
tion and in particular (-)-cocaine blood concentration. 
In addition, the present invention is directed to a novel and 
unique method for developing mutants which have enhanced 
catalytic efficiency. The generation method includes both a 
computational portion and an experimental portion. With 
regard to the computational portion, a variety of state of the 
art computational techniques including molecular modeling, 
molecular dynamics (MD) simulations and hybrid quantum 
10 mechanical/molecular mechanical (QM/MM) calculations, 
provide a virtual screening of possible BChE mutants. This 
virtual screening predicts which mutation will lead to a more 
stable transition state for a rate-determining step compared to 
the corresponding separated reactants, i.e., free cocaine and 
15 free enzyme. The more stable the transition state, the lower 
the energy barrier, and the higher the catalytic efficiency. 
Following the computational portion, an experimental test is 
then conducted on the possible mutants of the computation 
portion. The experimental test includes site-directed 
20 mutagenesis, protein expression, and enzyme activity assay. 
The experimental tests are conducted on mutants which are 
predicted to have a high catalytic efficiency against (-)-co-
caine than the wild-type BChE and/or other known BChE 
mutants against (-)-cocaine. Thus, the present method iden-
25 tifies or predicts mutants having high catalytic activity for 
cocaine hydrolysis by performing molecular modeling and 
MD simulations on the transition state structures of possible 
mutants ofBChE. This method is an improvement over tra-
ditional random-search approaches, which, given the com-
30 plex catalytic mechanism of cocaine hydrolysis, makes it 
difficult to improve the catalytic activity ofBChE for cocaine 
hydrolysis. 
The present invention in one form, concerns a butyryl cho-
linesterase variant peptide comprising an amino acid 
35 sequence selected from the group consisting of SEQ ID NOS: 
2,4, 6, 8, 10, 12, 14, 16, 18,20,22,24,26,28,and30. 
The present invention in another form thereof concerns a 
nucleic acid molecule comprising a nucleic acid sequence 
which encodes a butyrylcholinesterase variant peptide, the 
40 nucleic acid sequence selected from the group consisting of 
SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 
and 29. 
The present invention in another form thereof concerns a 
pharmaceutical composition comprising a butyrylcholinest-
45 erase variant polypeptide comprising an amino acid sequence 
selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 
10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30; and a suitable 
pharmaceutical carrier. 
In addition, the aforementioned mutant amino acid 
sequences can be truncated without substantially affecting 
the catalytic activity so that amino acid residues 1-67 and 
443-574 can be removed without substantially affecting the 
catalytic activity of the enzyme. SEQ ID NOS: 4, 10, 16, 22 50 
and 28 are the amino acid sequences for residue 68-142 
corresponding to mutants 1-5, respectively. In addition, with 
regard to mutants 1-4, it was found that amino acid residues 
before 117 and after 438 could be removed without sub stan-
The present invention in another form thereof concerns a 
method for treating a cocaine-induced condition comprising 
administering to an individual an effective amount ofbutyryl-
cholinesterase variant peptide having an amino acid sequence 
selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8, 
10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, to lower blood 
tially changing the activity of the mutant enzymes, resulting 55 
in truncated amino acid sequences having SEQ ID NOS: 6, 
cocaine concentration. 
The present invention is another form thereof concerns a 
method for treating a cocaine induced condition comprising 
administering to an individual an effective amount of a phar-
maceutical composition comprising a butyrylcholinesterase 
12, 18 and 24, respectively. Finally with regard to mutant 5, 
amino acid residues before 117 and after 441 could be 
removed without substantially changing its activity resulting 
in SEQ ID NO: 30. 
These aforementioned truncated sequences all of with 
similar catalytic activity is based on protein structures. 
60 variant having an amino acid sequence selected from the 
group consisting of SEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18, 
20, 22, 24, 26, 28, and 30, and suitable pharmaceutical carrier 
of claim 3 to an individual in an effective amount to lower Further, the present invention is directed to a novel and 
unique pharmaceutical composition which comprises a 
butyrylcholinesterase variant, namely mutants 1-5, along 65 
with a suitable pharmaceutical carrier. The pharmaceutical 
composition can be administered to an individual in an effec-
blood cocaine concentration. 
The present invention in yet another form thereof concerns 
a method for generating butyrylcholinesterase mutants. The 
method includes generating an initial structure of the transi-
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tion state structure for the rate-determining step of the 
cocaine hydrolysis catalyzed by a possible butyrylcholinest-
erase mutant. A sufficiently long time molecular dynamics 
simulation is performed on the transition state structure in 
water to have a stable molecular dynamics trajectory. The 
molecular dynamics trajectory is analyzed and the hydrogen 
bonding energies are estimated between the carboxyl oxygen 
8 
2A depicts BChE (-)-cocaine non-prereactive complex; FIG. 
2B depicts BChE (-)-cocaine prereactive complex, FIG. 2C 
depicts BChE (+)-cocaine non-prereactive complex; and 
FIG. 2D depicts BChE (+)-cocaine prereactive complex. 
FIG. 3A shows the (-)-cocaine rotation in the BChE active 
site for the non-prereactive complex to the prereactive com-
plex hindered by some residues at positions Y332, A328, and 
F329 residues in the non-prereactive complexes which are of the (-)-cocaine benzyl ester and the oxyanion hole of the 
possible butyryl cholinesterase mutant. If the overall hydro-
gen binding energy between the carboxyl oxygen of the (-)-
cocaine benzyl ester and the possible butyrylcholinesterase 
mutant, in the transition state, is stronger than the overall 
hydrogen binding energy between the carboxyl oxygen of the 
(-)-cocaine benzyl ester and the wild-type butyrylcholinest-
erase, optionally, hybrid quantum mechanical/molecular 
mechanical (QM/MM) geometry optimization is performed 
1 o significantly different from the corresponding positions in the 
prereactive complex; and FIG. 3B shows the (+)-cocaine 
rotation in the BChE active site where none of the aforemen-
tioned residues hinders the (+)-cocaine rotation in the BChE 
active site from the non-prereactive complex to the prereac-
15 tive complex in accordance with the present invention. 
to refine the molecular dynamics-simulated structure, the 
hydrogen binding energies are calculated and the energy bar-
rier is evaluated. Finally, the butyrylcholinesterase mutant is 
generated. 
FIG. 4A depicts the (-)-cocainerotation in the active site of 
A328W/Y332A; FIG. 4B depicts the (-)-cocaine rotation in 
the active site of A328W/Y332G BChE from the non-preac-
20 tive complex to the prereactive complex; and FIG. 4C depicts 
the (-)-cocaine rotation in the active site of wild-type BChE. 
In various alternative embodiments, the generating anini-
tial structure of the transition state structure is based on reac-
tion coordinate calculations for the wild-type butyrylcho- 25 
linesterase. The generating butyrylcholinesterase mutant 
includes performing site-directed mutagenesis on a nucleic 
acid sequence which includes wild-type butyrylcholinest-
erase to generate the mutant butyrylcholinesterase nucleic 
30 
acid sequence. Using the mutant butyrylcholinesterase 
nucleic acid sequence, the protein encoded by the mutant 
nucleic acid sequences is expressed to produce mutant 
butyrylcholinesterase and catalytic activity assay is per-
formed on the mutant butyrylcholinesterase. 
35 The hybrid quantum mechanical/molecular mechanical 
geometry optimization may include calculating the hydrogen 
binding energies and evaluating the energy barriers only if the 
overall hydrogen binding energy between the carboxyl oxy-
gen of the (-)-cocaine benzyl ester and the possible butyryl-
40 
cholinesterase mutant, in the transition state, is stronger than 
known butyryl cholinesterase mutants against (-)-cocaine. 
In yet another alternative further embodiment, the method 
for generating butyrylcholinesterase mutants further includes 
determining the rate-limiting step in the hydrolysis of (-)-
45 
cocaine by the possible butyryl cholinesterase mutant by con-
ducting molecular dynamics simulations and quantum 
mechanical/molecular mechanical calculations relating to the 
transition states for other reaction steps between (-)-cocaine 
by the possible butyryl cholinesterase mutant and calculating 
50 
respective energy barriers, thereby establishing which of the 
reaction steps is the rate-determining one. 
55 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 are plots of distances in the MD simulation (-)-
cocaine binding withA328W/Y332G BChE versus the simu-
lation time, along with root-mean-square deviation (RMSD) 60 
in the enzyme-substrate complexes where FIG. lA represents 
the non-prereactive enzyme-substrate complexes; and FIG. 
lB represents the prereactive enzyme-substrate complexes in 
accordance with the present invention. 
FIG. 2 shows the binding of structures of the simulated 65 
non-prereactive and prereactive complexes of wild-type 
BChE binding with two entomers of cocaine in which FIG. 
FIG. SA is a plot of the key internuclear distances (in A) 
versus the time in the simulated TS 1 structure for (-)-cocaine 
hydrolysis catalyzed by A328W/Y332A; and FIG. SB for 
A199S/A328W/Y332G BChE. 
FIG. 6 is a plot of key internuclear distances (in A) versus 
the time in the simulated TS 1 structure for (-)-cocaine 
hydrolysis catalyzed by A199S/S287G/A328W/Y332G 
BChE. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
The present invention has two major improvements over 
the prior art. The first is the presently discovered BChE 
mutants, mutant 1, A199S/A328W/Y332G; mutant 2, 
A199S/F227A/A328W/Y332G; mutant 3, A199S/S287G/ 
A328W/Y332G; mutant 4, A199S/F227A/S287G/A328W/ 
Y332G; and mutant 5, A199S/F227A/S287G/A328W/ 
E441D each have a significantly higher catalytic efficiency. 
The second improvement is concerning the mutant designing 
or discovering process. 
The BChE mutants 1-5 have full length amino acid 
sequences, SEQ ID NOS: 2, 8, 14, 20, and 26, respectively, 
which are encoded by nucleic acid sequences having SEQ ID 
NOS: 1, 7, 13, 19, and 25, respectively. Table 1 summarizes 
the catalytic efficiency against (-)-cocaine for the five 
mutants. 
In addition to the full length BChE mutants, the respective 
amino acid sequence can be truncated without substantially 
affecting the respective catalytic activity. With all mutants, 
residues 1-67 and 443-574 can be removed without substan-
tially affecting the catalytic activity of the respective mutant 
BChE. Further, with regard to mutant 1-4, amino acids 1-116 
and 439-57 4 can be omitted without substantially affecting its 
respective catalytic activity. With regard to mutant 5, amino 
acid residues 1-116 and 442-57 4 can be omitted without 
substantially affecting its catalytic activity. Table 1 also pro-
vides a summary of amino acid SEQ ID NOS and correspond-
ing nucleic acid SEQ ID NOS for the aforementioned trun-
cated mutant BChE sequences. 
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TABLE 1 
Partially 
Truncated Nucleic SEQIDNO 
Amino Amino Acid Sequence SEQ ID NO. for Corresponding To SEQ IDNO. Catalytic 
Acid Nucleic Acid Corresponding To Amino Acid Amino Acid for Amino Efficiency 
Mutant Substi- Acid SEQ SEQID Amino Acid Residues Residues Acid Residues Against 
Number luting IDNO. NO. Residues 68-442 68-442 117-438/441 * 117-438/441 * (-)-cocaine 
A199S/ 2 4 65-fold 
A328W/ 
Y332G 
2 A199S/ 7 9 10 11 12 148-fold 
F227A/ 
A328W/ 
Y332G 
A199S/ 13 14 15 16 17 18 456-fold 
S287G/ 
A328W/ 
Y332G 
4 A199S/ 19 20 21 22 22 24 1,003-fold 
F227A/ 
S287G/ 
A328W/ 
Y332G 
A199S/ 25 26 27 28 29 30 445-fold 
F227A/ 
S287G/ 
A328W/ 
E441D 
(*Amino acid residues 117-438 for mutants 1-4 and residues 117-441 for mutant 5.) 
The BChE variant polypeptide, e.g., SEQ ID NOS: 2, 4, 6, 
8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30 can be 
30 formulated in a pharmaceutical composition along with a 
mined in each case of application by one of ordinary skill in 
the art using only routine experimentation. 
A unique method was used to determine potential BChE 
mutants with projected increased catalytic activity for the 
hydrolysis of cocaine. The method provides a unique 
approach which first models the potential BChE mutant inter-
suitable pharmaceutical carrier known to one skilled in the 
art. 
The present BChE variant polypeptides can be used in 
treating a cocaine-induced condition by administering to an 
individual, an effective amount of one of the BChE variant 
polypeptides, i.e., SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 
20, 22, 24, 26, 28, and 30, to lower blood cocaine concentra-
tion. The BChE variant polypeptide may be administered in 
the form of a pharmaceutical composition in which the BChE 
variant is included with a suitable pharmaceutical carrier. 
Treatment of a cocaine induced condition using one of the 
aforementioned BChE variant polypeptides can be done in 
accordance with Zhan eta!., page 2463. 
The preferred dose for administration of a butyrylcho-
linesterase or peptide composition in accordance with the 
present invention is that amount which will be effective in 
lowering (-)-cocaine concentration in a patient's blood-
stream, and one would readily recognize that this amount will 
vary greatly depending on the nature of cocaine consumed, 
e.g., injected or inhaled, and the condition of a patient. An 
"effective amount" of butyrylcholinesterase mutant or phar-
maceutical agent to be used in accordance with the invention 
is intended to mean a nontoxic but sufficient amount of the 
agent, such that the desired prophylactic or therapeutic effect 
is produced. Thus, the exact amount of the enzyme or a 
particular agent that is required will vary from subject to 
subject, depending on the species, age, and general condition 
of the subject, the severity of the condition being treated, the 
particular carrier or adjuvant being used and its mode of 
administration, and the like. Similarly, the dosing regimen 
should also be adjusted to suit the individual to whom the 
composition is administered and will once again vary with 
age, weight, metabolism, etc. of the individual. Accordingly, 
the "effective amount" of any particular butyrylcholinest-
erase composition will vary based on the particular circum-
stances, and an appropriate effective amount may be deter-
35 action with cocaine followed by generating the BChE mutant 
if the predicted model indicates that the BChE variant should 
have enhanced catalytic activity. The method includes gener-
ating an initial structure of the transition state structure for the 
rate-determining step for the cocaine hydrolysis catalyzed by 
40 a possible BChE mutant. A sufficiently long time molecular 
dynamics simulation is performed on the transition state 
structure in water to have a stable molecular dynamics trajec-
tory. The molecular dynamics trajectory is analyzed and the 
hydrogen binding energies are estimated between the car-
45 boxy! oxygen of the (-)-cocaine benzoyl ester and the oxya-
nion hole of the possible BChE mutant. If the overall hydro-
gen binding energy between the carboxyl oxygen of the (-)-
cocaine benzoyl ester and the possible BChE mutant, in the 
transition state, is stronger than the overall hydrogen binding 
50 energy between the carboxyl oxygen of the (-)-cocaine ben-
zoyl ester and the wild-type BChE, hybrid quantum mechani-
cal/molecular mechanical (QM/MM) geometry optimization 
is performed to refine the molecular dynamics-simulated 
structure, the hydrogen binding energies are calculated and 
55 the energy barrier is evaluated. The QM/MM calculations 
make the computational predictions more reliable. Finally, 
the BChE mutant is generated. 
With regard to the molecular dynamics (MD) simulations 
and quantum mechanical/molecular mechanical (QM/MM) 
60 calculations, the first chemical reaction step of (-)-cocaine 
hydrolysis catalyzed by butyrylcholinesterase (BChE) 
mutants and, when needed, other reaction steps are modeled 
and calculated using molecular dynamics simulations and 
QM/MM calculations. Following this modeling, mutant 
65 BChE' s are created using site-directed mutagenesis followed 
by protein expression. The aforementioned five mutants were 
identified by computational analysis and generated by site-
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directed mutagenesis which have significantly enhanced (-)-
cocaine hydrolysis catalytic efficiency compared with wild-
type BChE. 
In the present method computational analysis in the form 
of molecular modeling of a potential BChE mutant and MD 
simulations and QM/MM calculations provide virtual screen-
ing of possible BChE mutants which have predicted enhanced 
catalytic activity for (-)-cocaine. For example, the MD simu-
lations and QM/MM calculations predict which mutation will 
lead to a more stable transition state for the rate determining 
step compared to the corresponding separated reagents, i.e., 
free cocaine and free possible mutant BChE, where the more 
stable transition state leads to a lower energy barrier and 
higher predicted catalytic efficiency. Only after the computa-
tional analysis predicts enhanced catalytic efficiency, is site-
directed mutagenesis conducted on wild-type BChE nucleic 
acid sequence to generate a mutant nucleic acid sequence 
which is then used to express a mutant BChE protein. The 
mutant BChE protein is then used in catalytic assays to deter-
mine the catalytic efficiency against (-)-cocaine. 
The use of predictive, computational modeling of the 
present method for identifying mutant BChE candidates and 
the resulting mutant BChE are novel and unexpected over 
prior conventional methods which will now be readily appar-
ent to one of ordinary skill in the art. 
Using the present method, most discovered new mutants 
include a specific mutation (Y332G) on residue #332. No 
prior BChE mutant having the Y332G mutation had ever been 
reported previously; only mutations Y332A and Y332M on 
residue #332 had been tested previously by other researchers. 
Prior to the present invention, there was no reason to expect 
that a mutant including Y332G mutation should be better than 
the corresponding mutant including Y332A mutation or 
Y332M. Thus, the present mutants with a Y332G mutation 
which have enhanced catalytic activity represent a surprising 
and unexpected result over prior BChE mutants. 
A Y332G mutant (single mutation) was first tested and 
found that the Y332G mutant had a slightly low (or approxi-
mately equal) catalytic efficiency than the wild-type. So, only 
12 
docking, molecular dynamics, quantum mechanics (QM), 
and hybrid quantum mechanics/molecular mechanics (QM/ 
MM) were used for the rational design of the BChE mutants. 
The combined use of these computational techniques, includ-
ing QM and QM/MM, led to the study of the detailed reaction 
coordinate of the BChE-catalyzed hydrolysis of cocaine 
which, for the first time, provided the detailed structures of all 
transition states and intermediates existing in the reaction 
process and the corresponding energetics. These extensive 
10 computational modeling and simulation studies provided for 
the rational design of possible BChE mutants that not only 
can improve the BChE-cocaine binding, but also can speedup 
the subsequent chemical reaction process. As a result, one can 
now quickly discover the BChE mutants with the signifi-
15 cantly improved catalytic efficiency. 
In addition, to the differences mentioned above, the present 
molecular modeling of the BChE-cocaine binding also differs 
from the prior modeling. The molecular modeling in the prior 
art considered only one binding mode for each BChE-cocaine 
20 system, without modeling the possible cocaine rotation in the 
BChE active site after the binding. The present method con-
siders two different binding modes for each BChE-cocaine 
system and the structural transformation between them: non-
prereactive and prereactive BChE-cocaine complexes. The 
25 present modeling provides more detailed information about 
the BChE-cocaine binding and the subsequent structural 
transformation. 
The present method includes molecular dynamics simula-
tions performed on the cocaine binding with both the wild-
30 type BChE and the mutants whereas prior molecular dynam-
ics simulations were only performed on the cocaine binding 
with the wild-type BChE. As is shown below in the following 
experiments, the computational prediction could be com-
pletely wrong without directly modeling and simulating 
35 cocaine binding with the proposed mutants. 
The present invention will now be discussed with regard to 
the following non-limiting examples in the form of experi-
ments which are provided to enhance understanding of the 
present invention but in no way limit its scope or applicability. 
an appropriate combination of different mutations on differ- 40 
ent residues could make the enzyme more active. As seen 
below, the prior art did not reveal that any of the particular 
combinations tested was expected to have an improved cata-
lytic efficiency. The present method is based on the present 
unique, extensive computational modeling and simulations of 45 
the detailed catalytic mechanism for both the wild-type BChE 
and the mutants. 
Experiment 1 
Computational Study of Cocaine Binding with 
Wild-Type and Mutant BChE's for A328WN332G, 
A328WN332A, andA328WN332AN419S 
A detailed computational study of cocaine binding with 
wild-type and mutant BChE's starting from the available 
X-ray crystal structure of wild-type BChE was performed. 
The primary improvement of the present method over the 
prior art is that high-performance computational modeling 
and simulations of the detailed catalytic mechanism are per-
formed, which includes modeling how cocaine binds with 
BChE and the subsequent structural transformation and 
chemical reaction process. The prior art only considered the 
cocaine binding with the enzyme (BChE) and was unable to 
examine the detailed catalytic reaction process after the 
BChE-cocaine binding. When molecular modeling was lim-
ited to studying the BChE-cocaine binding, one could only 
design a mutation to improve the BChE-cocaine binding 
without knowing whether the mutation will also speedup the 
subsequent chemical reaction process or not. 
50 The simulated mutants include A328WN332G, A328W/ 
Y332A, and A328WN332AN419S, as simple geometric 
consideration of the binding site suggests that these mutations 
could be important for changing the (-)-cocaine rotation from 
the non-prereactive complex to the prereactive complex. Wet 
55 experimental tests were conducted on the catalytic activity of 
these mutants for (-)-cocaine in order to verifY the computa-
tional predictions. All of the obtained results clearly demon-
strate that molecular modeling and MD simulations of 
cocaine binding with BChE mutants provide a reliable com-
60 putational approach to the rational design of high-activity 
mutants ofBChE for the (-)-cocaine hydrolysis. To overcome the obstacles of prior challenges to using 
computational techniques such as molecular docking and 
molecular dynamics simulation previously used by others 
which were based on an empirical force field which cannot be 
used to perform necessary reaction coordinate calculations 65 
for the catalytic reaction process, a variety of state-of-the-art 
computational techniques of homology modeling, molecular 
3D Model ofBChE. 
The initial coordinates of human BChE used in the com-
putational studies came from the X-ray crystal structure 
deposited in the Protein Data Bank (pdb code: !POP). The 
missing residues (D2, D3, E255, D378, D379, N455, L530, 
E531, and M532) in the X-ray crystal structure were built 
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using the automated homology modeling tool Modeler dis-
closed by Sali, A.; Blundell, T. L. J. Mol. Biol. 1990, 212 403, 
and Sali, A.; Blundell, T. L. J. Mol. Biol. 1993, 234, 779, 
herein incorporated by reference, and Insightii software (Ac-
celrys, Inc.) with the default parameters. 
Molecular Docking. 
Molecular docking was performed for each non-prereac-
tive protein-ligand binding complex. The binding site was 
defined as a sphere with an approximately 15 A radius around 
the active site residueS 198. The amino acid residues included 
in the binding site model are not contiguous in the protein. 
Cocaine, considered as a ligand, was initially positioned at 17 
A in front of S 198 of the binding site. Each BChE-cocaine 
binding complex was energy-minimized by using the steepest 
descent algorithm first until the maximum energy derivative 
is smaller than 4 kcal/mol/ A and then the conjugated gradient 
algorithm until the maximum energy derivative is smaller 
than 0.001 kcal/mol/A. The energy minimization was fol-
lowed by a 300 ps molecular dynamics (MD) simulation at 
T=298 K with a time step of 1 fs. During the energy minimi-
zation and MD simulation, only cocaine and the residues of 
BChE included in the binding site were allowed to move, 
while the remaining part of the protein was fixed. The energy-
minimization and MD simulation for these processes were 
performed by using the Amber force field implemented in the 
Discover_3/Insightii calculation engine, disclosed by Cor-
nell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, Jr., K. 
M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. 
W.; Kollman, P. A. J. Am. Chern. Soc. 1995, 117, 5179. The 
non-bonded cut-off method and the dielectric constant were 
set up to group based (12 A cut-off distance) and distance 
dependent, respectively ( E=4r) in accordance with Harvey, S. 
C. Proteins 1989, 5, 78-92, herein incorporated by reference. 
Molecular Dynamic Simulation in Water. 
The initial coordinates used in the MD simulation of the 
non-prereactive complexes were determined by using the 
molecular docking procedure described above, whereas the 
initial coordinates used in the MD simulation of the prereac-
tive complexes were obtained from superimposing backbone 
of the X-ray crystal structure to that of the previously dis-
closed simulated prereactive complex of Zhan et a! between 
cocaine and a homology model of wild-type BChE. Each 
BChE-cocaine binding complex was neutralized by adding 
two chloride counterions and was solvated in a rectangular 
box of TIP3P water molecules with a minimum solute-wall 
distance of 10 A. The general procedure for carrying out the 
MD simulations in water is similar to that used in our previ-
ously reported other computational studies such as those in 
Zhan eta! and (a) Zhan, C.-G.; Norberta de Souza, 0.; Rit-
tenhouse, R.; Ornstein, R. L. J. Am. Chern. Soc. 1999, 121, 
7279, (b) Koca, J.; Zhan, C.-G.; Rittenhouse, R.; Ornstein, R. 
L. J. Am. Chern. Soc. 2001, 123, 817, (c) Koca, J.; Zhan, 
C.-G.; Rittenhouse, R. C.; Ornstein, R. L. J. Comput. Chern. 
2003, 24, 368, herein all incorporated by reference. These 
simulations were performed by using the Sander module of 
Amber7 program as taught by Case, D. A.; Pearlman, D. A.; 
Caldwell, J. W.; Cheatham III, T. E.; Wang, J.; Ross, W. S.; 
Simmerling, C. L.; Darden, T. A.; Merz, K. M.; Stanton, R. V.; 
Cheng, A. L.; Vincent, J. J.; Crowley, M.; Tsui, V.; Gohlke, H.; 
Radmer, R. J.; Duan, Y.; Pitera, J.; Massova, I.; Seibel, G. L.; 
Singh, U. C.; Weiner, P. K.; Kollman, P.A. (2002),AMBER 7, 
University of California, San Francisco, herein incorporated 
by reference. The solvated system was optimized prior to the 
MD simulation. First, the protein-ligand was frozen and the 
solvent molecules with counterions were allowed to move 
during a 5000-step minimization with the conjugate gradient 
algorithm and a 5 ps MD run at T=300 K. After full relaxation 
14 
and the entire solvated system was energy-minimized, the 
system was slowly heated from T=10 K to T=300 Kin 30 ps 
before the production MD simulation for 500 ps. The full 
minimization and equilibration procedure was repeated for 
each mutant. The MD simulations were performed with a 
periodic boundary condition in the NPT ensemble at T=300 K 
with Berendsen temperature coupling and constant pressure 
(P=1 atm) with isotropic molecule-based scaling disclosed in 
Berendsen, H. C.; Postma, J. P. M.; van Gunsteren, W. F.; 
10 
DiNola,A.; Haak, J. R.J. Camp. Phys. 1984,81, 3684,herein 
incorporated by reference. The SHAKE algorithm of Ryck-
aert, J.P.; Ciccotti, G.; Berendsen, H. C.J. Camp. Phys. 1977, 
23, 327 (herein incorporated by reference) was applied to fix 
all covalent bonds containing a hydrogen atom, a time step of 
2 fs was used, and the non-bond pair list was updated every 10 
15 steps. The pressure was adjusted by isotropic position scaling. 
The particle mesh Ewald (PME) method of Essmann, U.; 
Perera, L.; Berkowitz, M. L.; Darden, T. A.; Lee, H., Peder-
sen; L. G. J. Chern. Phys. 1995, 98, 10089, herein incorpo-
rated by reference, was used to treat long-range electrostatic 
20 interactions.Aresidue-based cutoff oflO A was applied to the 
noncovalent interactions. During the 500 ps production MD 
simulation, the coordinates of the simulated complex were 
saved every 1 ps. 
Molecular docking and MD simulation procedures 
25 described above were performed to study cocaine binding 
with wild-type BChE and three mutants, i.e., A328W/ 
Y332A, A328W/Y332A/Y419S, and A328W/Y332G. For 
each protein system (wild-type or mutant BChE), the protein 
binding with cocaine was considered in both the non-prere-
30 active and prereactive enzyme-substrate complexes. 
Most of the MD simulations in water were performed on a 
supercomputer, Superdome (shared-memory, with 4 nodes 
and 256 processors), at the Center for Computational Sci-
ences, University of Kentucky. The other computations were 
carried out on SGI Fuel workstations and a 34-processors 
35 IBM x335 Linux cluster. 
Experimental Procedure. 
Site-directed mutagenesis of human BChE eDNA was per-
formed by the QuikChange method of Braman, J.; Papworth, 
C.; Greener, A. Methods Mol. Biol. 1996, 57, 5731, herein 
40 incorporated by reference. Mutations were generated from 
wild-type human BChE in a pRc/CMV expression plasmid in 
accordance with Xie, W.; Altamirano, C. V.; Bartels, C. F.; 
Speirs, R. J.; Cashman, J. R.; Lockridge, 0. Mol. Pharmacal. 
1999, 55, 83, all herein incorporated by reference, kindly 
45 provided by Dr. Lockridge at University ofNebraska Medical 
Center. Using plasmid DNA as template and primers with 
specific base-pair alterations, mutations were made by poly-
merase chain reaction with Pfu DNA polymerase, for repli-
cation fidelity. The PCR product was treated with Dpn I 
endonuclease to digest the parental DNA template. Modified 
50 plasmid DNA was transformed into Escherichia coli, ampli-
fied, and purified. The DNA sequences of the mutants were 
confirmed by DNA sequencing. BChE mutants were 
expressed in human embryonic kidney cell line 293 T /17. 
Cells were grown to 80-90% confluence in 6-well dishes and 
55 then transfected by Lipofectamine 2000 complexes of 4 flg 
plasmid DNA per each well. Cells were incubated at 3 7° C. in 
a C02 incubator for 24 hours and cells were moved to 60-mm 
culture vessel and cultured for four more days. The culture 
medium [10% fetal bovine serum in Dulbecco's modified 
60 Eagle's medium (DMEM)] was harvested for a BChE activity 
assay. To measure cocaine and benzoic acid, the product of 
cocaine hydrolysis by BChE, we used sensitive radiometric 
assays based on toluene extraction of [3H]cocaine labeled on 
its benzene ring were used in accordance with Masson, P.; 
65 Xie, W., Froment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret, 
C.; Lockridge, 0. Biochim. Biophys. Acta 1999, 1433, 281, 
herein incorporated by reference. In brief, to initiate reac-
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tions, 100 nCi of [3 H]cocaine was mixed with 100 fll of 
culture medium. Reactions proceeded at 37° C. for varying 
times. Reactions were stopped by adding 300 fll of 0.02 M 
HCI, which neutralized the liberated benzoic acid while 
ensuring a positive charge on the residual cocaine. [3H]ben-
zoic acid was extracted by 1 ml of toluene and measured by 
scintillation counting. Finally, the measured time-dependent 
radiometric data were fitted to the kinetic equation so that the 
catalytic efficiency (kcaiKM) was determined. 
Depicted in FIG. 1 are plots of some important distances in 10 
the MD-simulated (-)-cocaine binding withA328W N332G 
BChE versus the simulation time, along with root-mean-
square deviation (RMSD) of the coordinates of backbone 
atoms in the simulated structure from those in the X-ray 15 
crystal structure. MD trajectories for other complexes were 
similar to these two in FIG. 1, although the simulated average 
distances are different. Summarized in Table 2 are the average 
values of some important geometric parameters in the simu-
lated complexes. 20 
a Refers to (-)-cocaine binding with wild-type human 
BChE or (-)-cocaine binding with a mutant BChE, unless 
indicated otherwise. 
6 Refers to (+)-cocaine binding with wild-type human 
BChE. 25 
c<D1>non and <D1> represent the average distances 
between the S198 QY atom and the carbonyl carbon of the 
cocaine benzoyl ester in the simulated non-prereactive and 
prereactive BChE-cocaine complexes, respectively. <D2>, 
<D3>, <D4> refer to the average values of the simulated 30 
distances from the carbonyl oxygen of the cocaine benzoyl 
ester to the NH hydrogen atoms of G 116, G 117, and A199 
residues, respectively. <0> is the average value of the dihedral 
angle formed by the S198 QY atom and the plane of the 35 
carboxylate group of the cocaine benzoyl ester. See Scheme 
2. 
d The root-mean-square deviation (RMSD) of the coordi-
nates ofbackbone atoms in the simulated structure from those 
in the X-ray crystal structure of BChE. "nonpre" and "pre" 40 
refer to the non-prereactive and prereactive BChE-cocaine 
complexes, respectively. 
TABLE2 
BChE- Average values of the 45 
cocaine geometric 12ararnetersc RMSDd 
bindinga <Dl>non <Dl> <D2> <D3> <D4> <8> non pre pre 
wild-type 5.60 3.27 5.77 2.71 3.37 67 1.14 1.27 
wild-type 7.64 3.69 2.88 2.30 2.83 61 1.15 1.13 50 
with(+)-
cocaineb 
A328W/ 7.11 3.87 3.30 2.14 3.01 51 1.58 1.65 
Y332A 
A328W/ 7.06 3.96 2.28 2.52 2.42 60 1.20 1.35 
Y332G 55 
A328W/ 5.18 5.84 5.64 4.56 6.97 164 2.66 2.62 
Y332A/ 
Y419S 
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FIG. 2 shows the binding structures of the simulated non-
prereactive and prereactive complexes of wild-type BChE 
binding with the two enantiomers of cocaine. In the non-
prereactive complexes with (-)- and (+)-cocaine, the methyl 
ester group of cocaine is positioned at the top of the H438 
backbone, while the cocaine benzoyl ester moiety is quasi-
parallel to the C-OY side chain ofS198 with a dihedral angle 
8 of -8° and 140°, respectively. 
Scheme 2. Hydrolysis of(-)-cocaine and (+)-cocaine. 
G116-NH 
' \~2 0 
D3 \ I 
G117-NH---------/6c....... Dl / ~ ------:/~4 I -------,H : ~ S198 
A199-NII 
Here, 8 refers to the dihedral angle formed by S 198 QY and 
the plane of carboxylate group of the cocaine benzoyl ester as 
shown in the structure diagram below. 
The simulated internuclear distances between the carbonyl 
oxygen of cocaine benzoyl ester group and the NH hydrogen 
ofG116, G117, andA199 are comparable for the two enan-
tiomers. The simulated average distances between the carbo-
nyl carbon of the benzoyl ester and S198 QY are 5.60 A and 
5.18 A for (-)- and (+)-cocaine, respectively. Comparing the 
simulated protein backbone structures to the X-ray crystal 
structure of Nicolet et a!, one can see from FIG. 1 that the 
RMSD values are all smaller than 1.3 A for the whole protein 
structures. 
The MD simulations of the prereactive complexes reveal 
that wild-type BChE binding with (-)-cocaine is essentially 
the same as the binding with (+)-cocaine in the binding site, 
except for the different positions of methyl ester group of the 
substrates. The simulated average distances between the car-
bonyl carbon of the benzoyl ester and S198 QY are 3.27 and 
3.69 A for (-)-cocaine and (+)-cocaine, respectively. More-
over, the (+)-cocaine is stabilized more effectively by the 
formation of strong hydrogen bonds with the backbone NH of 
aRefers to (-)-cocaine binding with wild-type human BChE or (-)-cocaine binding with a 
mutant BChE, unless indicated otherwise. 
~efers to (+)-cocaine binding with wild-type human BChE. 
c<Dl>non and <Dl> represent the average distances between the S198 QY atom and the 
carbonyl carbon of the cocaine benzoyl ester in the simulated non-prereactive and prereac-
tive BChE-cocaine complexes, respectively. <D2>, <D3>, <D4> refer to the average values 
of the simulated distances from the carbonyl oxygen of the cocaine benzoyl ester to the NH 
hydrogen atoms ofG116, G117, andA199 residues, respectively. <8> is the average value 
of the dihedral angle formed by the S198 QY atom and the plane of the carboxylate group of 
the cocaine benzoyl ester. See Scheme 2. 
residues G116, G117, and A199 as summarized above in 
60 Table 2. The cocaine benzoyl ester moiety is positioned quasi-
perpendicular to S 198 C-OY with a dihedral angle 8 of -67° 
and -61 o for (-)- and (+)-cocaine, respectively. 
dThe root-mean-square deviation (RMSD) of the coordinates of backbone atoms in the 
simulated structure from those in the X-ray crystal structure ofBChE. "nonpre" and "pre" 
refer to the non-prereactive and prereactive BChE-cocaine complexes, respectively. 
A comparison was made between the currently simulated 
structures of the BChE-cocaine binding with those simulated 
65 previously by using a homology model of BChE and it was 
noted that two major differences between the two sets of 
structures. By using the X-ray crystal structure in accordance 
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with Nicolet eta!, the acyl loop is positioned on the top of the 
cocaine benzoyl ester moiety of the cocaine, whereas the acyl 
loop is far from the cocaine benzoyl ester moiety in the 
structure simulated starting from the homology model of 
Zhan eta!. The RMSD of the coordinates ofbackbone atoms 
in the previously simulated prereactive BChE-(-)-cocaine 
complex from those in the X-ray crystal structure ofBChE is 
-2.0 A for the entire protein and -3 .0 A for the acy !loop. The 
RMSD value became -2.4 A for the entire protein and-3.3 A 10 
for the acyl loop, when the X-ray crystal structure was 
replaced by the MD-simulated prereactive BChE-(-)-cocaine 
complex starting from the X-ray crystal structure. Despite 
these structural differences, the benzoyl ester group of the 
ligand is still close to the key residues (S197, G116, and 15 
G 117) in the BChE binding site. Some significant differences 
are associated with the distances between the S198 QY atom 
and the carbonyl carbon of the cocaine benzoyl ester in non-
prereactive complexes. The average values of this distance in 20 
the non-prereactive complexes were -9.5 and -8.5 A for (-)-
and (+)-cocaine, respectively, when a homology model was 
used. Using the X-ray crystal structure to conduct the analy-
sis, corresponding average values became -5.6 and -5.2 A, 
respectively. Therefore, both (-)- and (+)-cocaine became 25 
closer to the binding site when the homology model was 
replaced by the X-ray crystal structure. However, no signifi-
cant changes of the binding in the prereactive complexes were 
observed when the used homology model was replaced by the 30 
X-ray crystal structure. The average values of the simulated 
distance between the S198 QY atom and the carbonyl carbon 
18 
be performed to help design BChE mutants that have higher 
catalytic activity for (-)-cocaine hydrolysis. 
In the simulatednon-prereactive complex, the average dis-
tance between the carbonyl carbon of cocaine benzoyl ester 
andS198 QY is 7.6AforA328WN332ABChEand 7.1 A for 
A328W/Y332G BChE, as seen in Table 2 above. In the simu-
lated prereactive complex, the average values of this impor-
tant internuclear distance become 3.87 and 3.96 A for 
A328WN332A and A328WN332G BChE's, respectively. 
Compared to the simulated wild-type BChE-(-)-cocaine pre-
reactive complex, the average distances between the carbonyl 
carbon of the cocaine benzoyl ester and S198 QY in the pre-
reactive complex of (-)-cocaine with A328W/Y332A and 
A328WN332G BChE's are all slightly longer, whereas the 
average distances between the carbonyl oxygen of the 
cocaine benzoyl ester and the NH ofG116, G117, andA199 
residues are all shorter. This provides evidence that (-)-co-
caine more strongly bind withA328WN332A andA328W/ 
Y332G BChE's in the prereactive complexes. More impor-
tantly, the (-)-cocaine rotation in the active site of A328W I 
Y332A and A328WN332G BChE's from the non-
prereactive complex to the prereactive complex did not cause 
considerable changes of the positions of A332 (or G332), 
W328, and F329 residues as seen in FIG. 4, compared to the 
(-)-cocaine rotation in the active site of wild-type BChE. 
These results provide evidence that A328WN332A and 
A328W/Y332G BChE's should be associated with lower 
energy barriers than the wild-type for the (-)-cocaine rotation 
from the non-prereactive complex to the prereactive complex. 
Further, (-)-cocaine binding with A328W N332G BChE is 
of the cocaine benzoyl ester in the prereactive complexes are 
always close to -3.5 A for both (-)-and (+)-cocaine no matter 
whether the X-ray crystal structure or homology model of 
BChE was used as the starting structure. The similar compu-
tational results obtained from the use of the X-ray crystal 
structure and homology model of BChE provides evidence 
that the fundamental structural and mechanistic insights 
obtained from the previous computational studies of Zhan et 
a! are reliable, despite the previous simulations were per-
formed by using the homology model when the X -ray crystal 
structure was not available. 
35 very similar to the binding withA328WN332A BChE, but 
the position change ofF329 residue caused by the (-)-cocaine 
rotation was significant only inA328WN332A BChE, thus 
Further, the simulated structures of the non-prereactive 
BChE-cocaine complexes were superimposed with the cor-
responding prereactive complexes. As shown in FIG. 3, the 
(-)-cocaine rotation in the BChE active site from the non-
prereactive complex to the prereactive complex is hindered 
by some residues as the positions ofY332, A328, and F329 
residues in the non-prereactive complex are significantly dif-
ferent from the corresponding positions in the prereactive 
complex, whereas none of these residues hinders the ( + )-
cocaine rotation in the BChE active site from the non-prere-
active complex to the prereactive complex because these resi-
dues stay in nearly the same positions in the two BChE-( + )-
cocaine complexes. 
(-)-Cocaine Binding with BChE Mutants. 
Now that the (-)-cocaine rotation from the non-prereactive 
complex to the prereactive complex has been known to be the 
rate-determining step of the BChE-catalyzed hydrolysis of 
(-)-cocaine as shown by Zhan et a!, useful BChE mutants 
should be designed to specifically accelerate the change from 
the non-prereactive BChE-(-)-cocaine complex to the prere-
active complex. The question is whether MD simulation can 
suggesting that the energy barrier for the (-)-cocaine rotation 
40 
inA328WN332G BChE should be slightly lower than that in 
A328WN332A BChE. 
Concerning (-)-cocaine binding with A328WN332A/ 
Y 419S BChE, Y 419 stays deep inside the protein and does not 
directly contact with the cocaine molecule. TheY 419S muta-
45 tion was tested because it was initially expected that this 
mutation would further increase the free space of the active 
site pocket so that the (-)-cocaine rotation could be easier. 
However, as seen in Table 2 above, the average distance 
between the carbonyl carbon of cocaine benzoyl ester and 
50 S198 QY atom in the simulated prereactive complex was as 
long as 5.84 A. The average distances between the carbonyl 
oxygen of the cocaine benzoyl ester and the NH hydrolysis 
atoms ofG116, G117, andA199 residues are between 4.56 
55 and 6.97 A; no any hydrogen bond between them. In addition 
to the internuclear distances, another interesting geometric 
parameter is the dihedral angle, 0, formed by S 198 QY and the 
plane of the carboxylate group of the cocaine benzoyl ester. 
As seen in Table 2, the 8 values in the prereactive complexes 
60 of cocaine with wild-type BChE and all of the BChE mutants 
other thanA328WN332A/Y419S BChE all slightly deviate 
from the ideal value of90° for the nucleophilic attack ofS 198 
QY at the carbonyl carbon of cocaine. The 0 value in the 
65 prereactive complex of (-)-cocaine with A328W/Y332A/ 
Y419S BChE is 164°, which is considerably different from 
the ideal value of 900. 
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Catalytic Activity. 
The aforementioned discussion provides evidence that the 
energy barriers for the (-)-cocaine rotation in A328W I 
Y332A and A328WN332G BChE's from the non-prereac-
tive complex to the prereactive complex, the rate-determining 5 
step for the BChE-catalyzed hydrolysis of (-)-cocaine, 
should be lower than that in the wild-type BChE. Thus, the 
MD simulations predict that both A328WN332A and 
A328W N332G BChE's should have a higher catalytic activ- 10 
ity than the wild-type BChE for (-)-cocaine hydrolysis. Fur-
ther, the MD simulations also suggest that the energy barrier 
for the (-)-cocaine rotation in A328W N332G BChE should 
be slightly lower than that in A328WN332A BChE and, 
therefore, the catalytic activity of A328W N332G BChE for 15 
the (-)-cocaine hydrolysis should be slightly higher than the 
activity of A328WN332A BChE. In addition, the MD simu-
lations predict that A328WN332A/Y419S BChE should 
have no catalytic activity, or have a considerably lower cata- 20 
lytic activity than the wild-type, for (-)-cocaine hydrolysis 
because (-)-cocaine binds with the mutant BChE in a way 
that is not suitable for the catalysis. 
The catalytic efficiency (kca/KM) of A328WN332A 
BChE for (-)-cocaine hydrolysis was reported to be 8.56x1 06 25 
Mmin-r, which is 9.39 times of the kca!KM value (9.11x105 
M min- 1) of the wild-type BChE. To examine these theoreti-
cal predictions of the relative activity for A328W N332G and 
A328WN332A/Y419S BChE's, aA328WN332A,A328W/ 30 
Y332G, and A328WN332A/Y419S BChE was produced 
through site-directed mutagenesis. To minimize the possible 
systematic experimental errors of the kinetic data, kinetic 
studies were performed with all of three mutants under the 
same condition and compared the catalytic efficiency of the 35 
A328WN332G and A328WN332AN419S to that of the 
A328W N332A for (-)-cocaine hydrolysis at benzoyl ester 
group. Based on the kinetic analysis of the measured time-
dependent radiometric data, the ratio of the k /KMvalue of 
ca 40 
A328WN332G BChE to the kca/KM value of A328W/ 
Y332A BChE for the (-)-cocaine hydrolysis was determined 
to be -2.08, or A328WN332G BChE has a kca!KM value of 
-1.78x107 Mmin- 1 for the (-)-cocaine hydrolysis. The radio-
metric data show no significant catalytic activity for A328W/ 45 
Y332A/Y419S BChE. These experimental data are consis-
tent with the theoretical predictions based on the MD 
simulations. 
Conclusion. 
Molecular modeling, molecular docking, and molecular 50 
dynamics (MD) simulations were performed to study cocaine 
binding with human butyrylcholinesterase (BChE) and its 
mutants, based on a recently reported X-ray crystal structure 
of human BChE. The MD simulations of cocaine binding 55 
with wild-type BChE led to average BChE-cocaine binding 
structures similar to those obtained recently from the MD 
simulations based on a homology model ofBChE, despite the 
significant difference found at the acyl binding pocket. This 
confirms the fundamental structural and mechanistic insights 60 
obtained from the prior computational studies of Zhan et a! 
based on a homology model ofBChE, e.g., the rate-determin-
ing step for BChE-catalyzed hydrolysis ofbiologically active 
(-)-cocaine is the (-)-cocaine rotation in the BChE active site 65 
from the non-prereactive BChE-(-)-cocaine complex to the 
prereactive complex. 
20 
The MD simulations further reveal that the (-)-cocaine 
rotation in the active site of wild-type BChE from the non-
prereactive complex to the prereactive complex is hindered 
by some residues such that the positions ofY332, A328, and 
F329 residues in the non-prereactive complex are signifi-
cantly different from those in the prereactive complex. Com-
pared to (-)-cocaine binding with wild-type BChE, (-)-co-
caine more strongly bind withA328WN332A andA328W/ 
Y332G BChE's in the prereactive complexes. More 
importantly, the (-)-cocaine rotation in the active site of 
A328WN332A andA328WN332G BChE's from the non-
prereactive complex to the prereactive complex did not cause 
considerable changes of the positions of A332 or G332, 
W3 28, and F3 29 residues. These results provide evidence that 
A328WN332A andA328WN332G BChE's are associated 
with lower energy barriers than wild-type BChE for the (-)-
cocaine rotation from the non-prereactive complex to the 
prereactive complex. Further, (-)-cocaine binding with 
A328WN332G BChE is very similar to the binding with 
A328WN332A BChE, but the position change ofF329 resi-
due caused by the (-)-cocaine rotation was significant only in 
A328WN332A BChE, thus suggesting that the energy bar-
rier for (-)-cocaine rotation inA328WN332G BChE should 
be slightly lower than that in A328W N332A BChE. It has 
also been demonstrated that (-)-cocaine binds withA328W/ 
Y332A/Y419S BChE in a way that is not suitable for the 
catalysis. 
Based on the computational results, bothA328WN332A 
andA328WN332G BChE's have catalytic activity for(-)-
cocaine hydrolysis higher than that of wild-type BChE and 
the activity of A328WN332G BChE should be slightly 
higher than that of A328WN332A BChE, whereas A328W I 
Y332A/Y419S BChE is expected to lose the catalytic activ-
ity. The computational predictions are completely consistent 
with the experimental kinetic data, providing evidence that 
the used computational protocol, including molecular mod-
eling, molecular docking, and MD simulations, is reliable in 
prediction of the catalytic activity of BChE mutants for (-)-
cocaine hydrolysis. 
Experiment 2 
MD Simulations and Quantum 
Mechanical/Molecular Mechanical (QM/MM) 
Calculations Relating to A199S/A328WN332G 
Mutant (Mutant 1) (SEQ ID NO: 1) 
Generally speaking, for rational design of a mutant enzyme 
with a higher catalytic activity for a given substrate, one needs 
to design a mutation that can accelerate the rate-determining 
step of the entire catalytic reaction process while the other 
steps are not slowed down by the mutation. Reported com-
putational modeling and experimental data indicated that the 
formation oftheprereactive BChE-(-)-cocaine complex (ES) 
is the rate-determining step of (-)-cocaine hydrolysis cata-
lyzed by wild-type BChE as disclosed by Sun eta!, Zhan eta! 
and Hamza, A.; Cho, H.; Tai, H.-H.; Zhan, C.-G. J. Phys. 
Chern. B 2005, 109, 4776, herein incorporated by reference, 
whereas the rate-determining step of the corresponding ( + )-
cocaine hydrolysis is the chemical reaction process consist-
ing of four individual reaction steps disclosed by Zhan et a! 
and shown in Scheme 3 and Scheme 4 below. 
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Scheme 3. Schematic representation of BChE-catalyzed 
hydrolysis of (-)-cocaine. Only QM-treated high-layer part 
60 
of the reaction system in the QM/MM calculations are drawn. 
Notation [H] refers to a non-hydrogen atom in the MM-
treated low -layer part of the protein and the cut covalent bond 65 
with this atom is saturated by a hydrogen atom. The dash lines 
in the transition state structures represent the transition bonds. 
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This mechanistic understanding is consistent with the 
experimental observation of Sun et a!, that the catalytic rate 
constant of wild-type BChE against (+)-cocaine is pH-depen-
dent, whereas that of the same enzyme against (-)-cocaine is 
independent of the pH. The pH-dependence of the rate con-
stant for (+)-cocaine hydrolysis is clearly associated with the 
protonation of H438 residue in the catalytic triad (S198, 
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H438, and E325). For the first and third steps of the reaction 
process, when H438 is protonated, the catalytic triad cannot 
function and, therefore, the enzyme becomes inactive. The 
lower the pH of the reaction solution is, the higher the con-
centration of the protonated H438 is, and the lower the con-
centration of the active enzyme is. Hence, the rate constant 
was found to decrease with decreasing the pH of the reaction 
solution for the enzymatic hydrolysis of (+)-cocaine. 
Based on the above mechanistic understanding, the efforts 10 
for rational design of the BChE mutants reported in literature 
have been focused on how to improve the ES formation 
process. Indeed, several BChE mutants, including A328W, 
A328WN332A, A328WN332G, and F227A/S287G/ 
A328WN332M, have been found to have a significantly 15 
higher catalytic efficiency (kca/KM) against (-)-cocaine; 
these mutants of BChE have an approximate 9 to 34-fold 
improved catalytic efficiency against (-)-cocaine. Experi-
mental observation also indicated that the catalytic rate con- 20 
stant of A328WN332A BChE is pH-dependent for both (-)-
and (+)-cocaine. The pH -dependence reveals that for both 
(-)- and (+)-cocaine, the rate-determining step of the 
hydrolysis catalyzed by A328WN332A BChE should be 
either the first or the third step of the reaction process. Further, 25 
if the third step were rate determining, then the catalytic 
efficiency of the A328W/Y332A mutant against (-)-cocaine 
should be as high as that of the same mutant against ( + )-
cocaine because the (-)-and (+)-cocaine hydrolyses share the 30 
same third and fourth steps (see Scheme 3). However, it has 
also been observed that the A328W N332A mutant only has 
a -9-fold improved catalytic efficiency against (-)-cocaine, 
whereas the A328WN332A mutation does not change the 
high catalytic activity against (+)-cocaine. This analysis of 35 
the experimental and computational data available in litera-
ture clearly shows that the rate-determining step of (-)-co-
caine hydrolysis catalyzed by the A328WN332A mutant 
should be the first step of the chemical reaction process. 
40 
Further, recently reported computational modeling also sug-
gests that the formation of the prereactive BChE-(-)-cocaine 
complex (ES) is hindered mainly by the bulky side chain of 
Y332 residue in wild-type BChE, but the hindering can be 
removed by the Y332A or Y332G mutation. Therefore, start- 45 
ing from theA328WN332A or A328WN332G mutant, the 
truly rational design of further mutation(s) to improve the 
catalytic efficiency of BChE against (-)-cocaine should aim 
to decrease the energy barrier for the first reaction step with-
50 
out significantly affecting the ES formation and other chemi-
cal reaction steps. 
28 
against (-)-cocaine. The prediction has been confirmed by 
wet experimental tests showing that the A199S/A328W/ 
Y332G mutant has a significantly improved catalytic effi-
ciency against (-)-cocaine. All of the obtained results clearly 
demonstrate that directly modeling the transition-state struc-
ture provides a reliable computational approach to the ratio-
nal design of a high-activity mutant of BChE against (-)-
cocame. 
MD Simulations. 
It should be stressed that a critical issue exists with regard 
to any MD simulation on a transition state. In principle, MD 
simulation using a classical force field (molecular mechanics) 
can only simulate a stable structure corresponding to a local 
minimum on the potential energy surface, whereas a transi-
tion state during a reaction process is always associated with 
a first-order saddle point on the potential energy surface. 
Hence, MD simulation using a classical force field cannot 
directly simulate a transition state without any restraint on the 
geometry of the transition state. Nevertheless, if one can 
technically remove the freedom of imaginary vibration in the 
transition state structure, then the number of vibrational free-
doms (normal vibration modes) for a nonlinear molecule will 
decrease from 3N-6. The transition state structure is associ-
ated with a local minimum on the potential energy surface 
within a subspace of the reduced vibrational freedoms, 
although it is associated with a first-order saddle point on the 
potential energy surface with all of the 3N-6 vibrational free-
doms. Theoretically, the vibrational freedom associated with 
the imaginary vibrational frequency in the transition state 
structure can be removed by appropriately freezing the reac-
tion coordinate. The reaction coordinate corresponding to the 
imaginary vibration of the transition state is generally char-
acterized by a combination of some key geometric param-
eters. These key geometric parameters are bond lengths of the 
forming and breaking covalent bonds for BChE-catalyzed 
hydrolysis of cocaine, as seen in Scheme 3. Thus, one just 
needs to maintain the bond lengths of the forming and break-
ing covalent bonds during the MD simulation on a transition 
state. Technically, one can maintain the bond lengths of the 
forming and breaking covalent bonds by simply fixing all 
atoms within the reaction center, by using some constraints on 
the forming and breaking covalent bonds, or by redefining the 
forming and breaking covalent bonds. It should be pointed out 
that the only purpose of performing such type of MD simu-
lation on a transition state is to examine the dynamic change 
of the protein environment surrounding the reaction center 
and the interaction between the reaction center and the pro-
tein environment. For this study, of interest is the simulated 
structures, as the total energies calculated in this way are 
The following rational design of a high-activity mutant of 
BChE against (-)-cocaine is based on detailed computational 
modeling of the transition state for the rate-determining step 
(i.e., the first step of the chemical reaction process). Molecu-
lar dynamics (MD) simulations and hybrid quantum 
mechanical/molecular mechanical (QM/MM) calculations 
were performed to model the protein environmental effects 
55 meaningless. 
on the stabilization of the transition-state structure for BChE- 60 
catalyzed hydrolysis of (-)-cocaine. The simulated and cal-
culated results indicate that the transition-state structure can 
be stabilized better by the protein environment in A199S/ 
A328WN332G mutant ofBChE than that in the wild-type. 65 
The computational modeling led to a prediction of the higher 
catalytic efficiency for the A199S/A328WN332G mutant 
The initial BChE structures used in the MD simulations 
were prepared based on the previous MD simulation in accor-
dance with Hamza et a! on the prereactive ES complex for 
wild-type BChE with (-)-cocaine in water by using Amber7 
program package. The previous MD simulations on the pre-
reactive BChE-(-)-cocaine complex (ES) started from the 
X -ray crystal structure ofNicolet eta! deposited in the Protein 
Data Bank (pdb code: !POP). The present MD simulation on 
the transition state for the first step (TS 1) was performed in 
such a way that bond lengths of the partially formed and 
partially broken covalent bonds in the transition state were all 
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constrained to be the same as those obtained from our previ-
ous ab initio reaction coordinate calculations on the model 
reaction system of wild-type BChE in accordance with Zhan 
et a!. The partially formed and partially broken covalent 
bonds in the transition state will be called "transition" bonds 
below, for convenience. A sufficiently long MD simulation 
with the transition bonds constrained should lead to a reason-
able protein environment stabilizing the reaction center in the 
transition-state structure simulated. Further, the simulated 10 
TS1 structure for wild-type BChE with (-)-cocaine was used 
to build the initial structures ofTS1 for the examined BChE 
mutants with (-)-cocaine; only the side chains of mutated 
residues needed to be changed. 
The partial atomic charges for the non-standard residue 15 
atoms, including cocaine atoms, in the TS1 structures were 
calculated by using the RESP protocol implemented in the 
Antechamber module of the Amber7 package following elec-
trostatic potential (ESP) calculations at ab initio HF/6-31G* 20 
level using Gaussian03 program known in the art. The geom-
etries used in the ESP calculations came from those obtained 
from the previous ab initio reaction coordinate calculations of 
Zhan eta!, but the functional groups representing the oxyan-
ion hole were removed. Thus, residues G116, G117, and 25 
A199 were the standard residues as supplied by Amber7 in the 
MD simulations. The general procedure for carrying out the 
MD simulations in water is essentially the same as that used 
in our previously reported other computational studies 30 
including Zhan eta!, Hamza eta! and (a) Zhan, C.-G.; Norb-
erta de Souza, 0.; Rittenhouse, R.; Ornstein, R. L. J. Am. 
Chern. Soc. 1999, 121,7279, (b) Koca, J.; Zhan, C.-G.; Rit-
tenhouse, R.; Ornstein, R. L. J. Am. Chern. Soc. 2001, 123, 
817, (c) Koca, J.; Zhan, C.-G.; Rittenhouse, R. C.; Ornstein, 35 
R. L.JComput. Chern. 2003,24,368, (d) Hamza,A.; Cho, H.; 
Tai, H.-H.; Zhan, C.-G. Bioorg. Med. Chern. 2005, 13, 4544, 
herein all incorporated by reference. Each aforementioned 
starting TS 1 structure was neutralized by adding chloride 
40 
counterions and was solvated in a rectangular box ofTIP3P 
water molecules with a minimum solute-wall distance of 10 A 
as described by Jorgensen, W. L.; Chandrasekhar, J.; Madura, 
J.; Klein, M. L. J. Chern. Phys. 1983, 79, 926, herein incor-
porated by reference. The total numbers of atoms in the sol- 45 
vated protein structures for the MD simulations are nearly 
70,000, although the total number of atoms of BChE and 
(-)-cocaine is only 8417 (for the wild-type BChE). All of the 
MD simulations were performed by using the Sander module 
50 
of Amber7 package. The solvated systems were carefully 
equilibrated and fully energy minimized. These systems were 
gradually heated from T=10 K to T=298.15 K in30ps before 
running the MD simulation at T=298.15 K for 1 ns or longer, 
making sure that a stable MD trajectory was obtained for each 55 
of the simulated TS1 structures. The time step used for the 
MD simulations was 2 fs. Periodic boundary conditions in the 
NPT ensemble at T=298.15 K with Berendsen temperature 
coupling and P=1 atm with isotropic molecule-based scaling 
were applied. The SHAKE algorithm was used to fix all 60 
covalent bonds containing hydrogen atoms. The non-bonded 
pair list was updated every 10 steps. The particle mesh Ewald 
(PME) method in accordance with Essmann, U.; Perera, L.; 
Berkowitz, M. L.; Darden, T. A.; Lee, H., Pedersen, L. G. J. 65 
Chern. Phys. 1995, 98, 10089, herein incorporated by refer-
ence, was used to treat long-range electrostatic interactions. A 
30 
residue-based cutoff of 10 A was utilized to the non-covalent 
interactions. The coordinates of the simulated systems were 
collected every 1 ps during the production MD stages. 
QM/MM Calculations. 
For each TS 1 structure examined, after the MD simulation 
was completed and a stable MD trajectory was obtained, all of 
the collected snapshots of the simulated structure, excluding 
those before the trajectory was stabilized, were averaged and 
further energy-minimized. The energy-minimized average 
structure (with the transition bonds constrained) was used as 
an initial geometry to carry out a further geometry optimiza-
tion by using the ONIOM approach of Dapprich, S.; Koma-
romi, I.; Byun, K. S.; Morokuma, K.; Frisch, M. J. J. Mol. 
Struct. (Theochem) 1999, 461, 1-21, herein incorporated by 
reference, implemented in the Gaussian03 program ofFrisch, 
M. J. eta! Gaussian 03, Revision A. 1, Gaussian, Inc., Pitts-
burgh, Pa., 2003, herein incorporated by reference. Two lay-
ers were defined in the present ONIOM calculation: the high 
layer, as depicted in Scheme 3 above, was calculated quantum 
mechanically at the ab initio HF /3-21 G level, whereas the low 
layer was calculated molecular mechanically by using the 
Amber force field as used in our MD simulation and energy 
minimization with theAmber7 program. The ONIOM calcu-
lations attheHF/3-21G:Amberlevel in this study area type of 
QM/MM calculations ofVreven, T.; Morokuma, K. J. Chern. 
Phys. 2000, 113, 2969-2975 and Frisch, M.; Vreven, T.; 
Schlegel, H. B.; Morokuma, K. J. Comput. Chern. 2003,24, 
760-769, herein both incorporated by reference. Previous 
reaction coordinate calculations with an active site model of 
wild-type BChE demonstrate that the HF/3-21G level is 
adequate for the geometry optimization of this enzymatic 
reaction system shown by Zhan et a!, although the final 
energy calculations for calculating the energy barriers must 
be carried out at a higher level. As depicted in Scheme 3, for 
all of these QM/MM calculations, the same part of the 
enzyme was included in the QM-treated high layer. So, the 
QM-treated high layer included (-)-cocaine, key functional 
groups from the catalytic triad (S198, H438, and E325), and 
the three residues, i.e., G116, G117, andA199 (or S199 for a 
particular mutant, see Scheme 4 ), of the possible oxyanion 
hole, whereas the entire enzyme structure of BChE was 
included in the MM-treated low layer. A language computer 
program was developed to automatically generate the input 
files for the ONIOM calculations following the MD simula-
tions and subsequent energy minimizations in order to make 
sure that the atom types used for all low-layer atoms are the 
same as what were used in the Amber7. During the TS1 
geometry optimization using the two-layer ONIOM, the 
length of a key transition C-0 bond was fixed which domi-
nates the reaction coordinate; all of the other transition bond 
lengths were relaxed. The C and 0 atoms in the key transition 
C-O bond are the carbonyl carbon of (-)-cocaine benzoyl 
ester and the OY atom of S 198, respectively, according to the 
previous reaction coordinate calculations with an active site 
model of wild-type BChE of Zhan eta!. 
Most of the MD simulations and QM/MM calculations 
were performed in parallel on an HP supercomputer (Super-
dome, with 256 shared-memory processors) at the Center for 
Computational Sciences, University of Kentucky. Some of 
the computations were carried out on a 34-processors IBM 
x335 Linux cluster and SGI Fuel workstations. 
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Scheme 4. 
Schematic representation of the first reaction step for (-)-cocaine hydrolysis 
catalyzed by a BChE mutant with an A199S mutation. 
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-continued 
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Scheme 4. Schematic representation of the first reaction 
step for (-)-cocaine hydrolysis catalyzed by a BChE mutant 
with anA199S mutation. 
Experimental Materials. 
Cloned pfu DNA polymerase and Dpn I endonuclease were 
obtained from Strata gene (La Jolla, Calif.). 3 H-(-)-cocaine 
(50 Ci/mmol) was purchased from PerkinElmer Life Sci-
ences (Boston, Mass.). The expression plasmid pRc/CMV 
was a gift from Dr. 0. Lockridge, University of Nebraska 
Medical Center (Omaha, Nebr.). All oligonucleotides were 
synthesized by the Integrated DNA Technologies, Inc. The 
QIAprep Spin Plasmid Miniprep Kit and Qiagen plasmid 
purification kit and QIAquick PCR purification kit were 
obtained from Qiagen (Santa Clarita, Calif.). Human embry-
onic kidney 293T/17 cells were fromATCC (Manassas, Va.). 
Dulbecco's modified Eagle's medium (DMEM) was pur-
chased from Fisher Scientific (Fairlawn, N.J.). Oligonucle-
otide primers were synthesized by the Integrated DNA Tech-
nologies and Analysis Facility of the University ofKentucky. 
3,3',5,5'-Tetramethylbenzidine (TMB) was obtained from 
Sigma (Saint Louis, Mo.). Anti -butyrylcholinesterase (mouse 
monoclonal antibody, Product #HAH002-01) was purchased 
from AntibodyShop (Gentofte, Denmark) and Goat anti-
mouse IgG HRP conjugate from Zymed (San Francisco, 
Calif.). 
Site-Directed Mutagenesis, Protein Expression, and BChE 
Activity Assay. 
Site-directed mutagenesis of human BChE eDNA was per-
formed by using the QuikChange method of Braman et a!. 
Mutations were generated from wild-type human BChE in a 
pRc/CMV expression plasmid in accordance with (a) Mas-
son, P.; Legrand, P.; Bartels, C. F.; Froment, M.-T.; Schopfer, 
L. M.; Lockridge, 0. Biochemistry 1997,36,2266, (b) Mas-
son, P.; Xie, W., Froment, M-T.; Levitsky, V.; Fortier, P.-L.; 
Albaret, C.; Lockridge, 0. Biochim. Biophys. Acta 1999, 
1433, 281, (c) Xie, W.; Altamirano, C. V.; Bartels, C. F.; 
Speirs, R. J.; Cashman, J. R.; Lockridge, 0. Mol. Pharmacal. 
1999, 55, 83, (d) Duysen, E. G.; Bartels, C. F.; Lockridge, 0. 
J. Pharmacal. Exp. Ther. 2002, 302, 751, (e) Nachon, F.; 
Nicolet, Y.; Viguie, N.; Masson, P.; Fontecilla-Camps, J. C.; 
Lockridge, 0. Eur. J. Biochem. 2002, 269, 630, herein all 
incorporated by reference. Using plasmid DNA as template 
and primers with specific base-pair alterations, mutations 
were made by polymerase chain reaction with Pfu DNA poly-
merase, for replication fidelity. The PCR product was treated 
34 
with Dpn I endonuclease to digest the parental DNA template. 
Modified plasmid DNA was transformed into Escherichia 
coli, amplified, and purified. The DNA sequences of the 
25 mutants were confirmed by DNA sequencing. BChE mutants 
were expressed in human embryonic kidney cell line 293T/ 
17. Cells were grown to 80-90% confluence in 6-well dishes 
and then transfected by Lipofectamine 2000 complexes of 4 
flg plasmid DNA per each well. Cells were incubated at 37° C. 
30 in a C02 incubator for 24 hours and cells were moved to 
60-mm culture vessel and cultured for four more days. The 
culture medium [10% fetal bovine serum in Dulbecco's 
modified Eagle's medium (DMEM)] was harvested for a 
35 BChE activity assay. To measure (-)-cocaine and benzoic 
acid, the product of (-)-cocaine hydrolysis catalyzed by 
BChE, sensitive radiometric assays were used based on tolu-
ene extraction of [3H]-(-)-cocaine labeled on its benzene ring 
in accordance with Sun eta!. In brief, to initiate the enzymatic 
40 reaction, 100 nCi of [3 H]-(-)-cocaine was mixed with 100 fll 
of culture medium. The enzymatic reactions proceeded at 
room temperature (25° C.) for varying time. The reactions 
were stopped by adding 300 fll of 0.02 M HCl, which neu-
tralized the liberated benzoic acid while ensuring a positive 
45 charge on the residual (-)-cocaine. [3 H]benzoic acid was 
extracted by 1 ml of toluene and measured by scintillation 
counting. Finally, the measured time-dependent radiometric 
data were fitted to the kinetic equation so that the catalytic 
efficiency (kca/KM) was determined along with the use of an 
50 enzyme-linked immunosorbent assay (ELISA) described 
below. 
Enzyme-Linked Immunosorbent Assay (ELISA). 
The ELISA buffers used in the present study are the same 
as those described in the literature such as (a) Brock, A.; 
55 Mortensen, V.; Loft, A. G. R.; Nergaard-Pedersen, B. J. Clin. 
Chern. Clin. Biochem. 1990,28,221-224, (b) Khattab,A. D.; 
Walker, C. H.; Johnston, G.; Siddiqui, M. K. Saphier, P. W. 
Environmental Toxicology and Chemistry 1994, 13, 1661-
1667, herein both incorporated by reference. The coating 
60 buffer was 0.1 M sodium carbonate/bicarbonate buffer, pH 
9.5. The diluent buffer (EIA buffer) was potassium phosphate 
monobasic/potassium phosphate monohydrate buffer, pH 
7 .5, containing 0.9% sodium chloride and 0.1% bovine serum 
albumin. The washing buffer (PBS-T) was 0.01 M potassium 
65 phosphate monobasic/potassium phosphate monohydrate 
buffer, pH 7.5, containing 0.05% (v/v) Tween-20. All the 
assays were performed in triplicate. Each well of an ELISA 
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structure corresponding to the A199S/A328WN332G 
mutant, mutant (1) (SEQ ID NO: 2). 
Table 3. Summary of the MD-simulated and QM/MM-
optimizedkey distances (inA) and the calculated total hydro-
gen-bonding energies (HBE, in kcal/mol) between the oxya-
nion hole and the carbonyl oxygen of (-)-cocaine benzoyl 
ester in the first transition state (TS 1 ). 
microtiter plate was filled with 100 fll of the mixture buffer 
consisting of 20 fll culture medium and 80 fll coating buffer. 
The plate was covered and incubated overnight at 4 o C. to 
allow the antigen to bind to the plate. The solutions were then 
removed and the wells were washed four times with PBS-T. 
The washed wells were filled with 200 fll diluent buffer and 
kept shaking for 1.5 h at room temperature (25° C.). After 
washing with PBS-T for four times, the wells were filled with 
100 fll antibody (1:8000) and were incubated for 1.5 h, fol-
lowed by washing for four times. Then, the wells were filled 
with 100 fll goat anti-mouse IgG HRP conjugate complex 
diluted to a final! :3000 dilution, and were incubated at room 
temperature for 1.5 h, followed by washing for four times. 
The enzyme reactions were started by addition of 100 fll 
substrate (TMB) solution. The reactions were stopped after 15 
15 min by the addition of 100 fll of 2 M sulfuric acid, and the 
absorbance was read at 460 nm using a Bio-Rad ELISA plate 
reader. 
10 Transition Distancea Total 
Hydrogen Bonding Revealed by the MD Simulations. 
In accordance with one aspect of the present invention, 20 
namely the generation of high-activity mutants of BChE 
against (-)-cocaine, the present invention includes predicting 
some possible mutations that can lower the energy of the 
transition state for the first chemical reaction step (TS 1) and, 
therefore, lower the energy barrier for this critical reaction 25 
step. Apparently, a mutant associated with the stronger hydro-
gen bonding between the carbonyl oxygen of (-)-cocaine 
benzoyl ester and the oxyanion hole of the BChE mutant in 
the TSl structure may potentially have a more stable TSl 
structure and, therefore, a higher catalytic activity for (-)- 30 
cocaine hydrolysis. Hence, the hydrogen bonding with the 
oxyanionhole in the TSl structure is a crucial factor affecting 
the transition state stabilization and the catalytic activity. The 
possible effects of some mutations on the hydrogen bonding 
were examined by performing MD simulations and QM/MM 35 
calculations on the TS 1 structures for (-)-cocaine hydrolysis 
catalyzed by the wild-type and various mutants BChE's. 
The MD simulation in water was performed for 1 ns or 
longer to make sure a stable MD trajectory was obtained for 
each simulated TSl structure with the wild-type or mutant 40 
BChE. The MD trajectories actually became stable quickly, 
so were the H . . . 0 distances involved in the potential 
hydrogen bonds between the carbonyl oxygen of (-)-cocaine 
and the oxyanion hole ofBChE. 
Depicted in FIG. 5 are plots of four important H ... 0 45 
distances in the MD-simulated TS 1 structure versus the simu-
lation time for (-)-cocaine hydrolysis catalyzed by A328W/ 
Y332A or A199S/A328WN332G BChE, along with the 
root-mean-square deviation (RMSD) of the simulated posi-
tions of backbone atoms from those in the corresponding 50 
initial structure. Traces D 1, D2, and D3 refer to the distances 
between the carbonyl oxygen of (-)-cocaine and the NH 
hydrogenofG116, G117, and S199, respectively. Trace D4 is 
the internuclear distance between the carbonyl oxygen of 
(-)-cocaine and the hydroxyl hydrogen of the S 199 side chain 55 
which exists only inA199S/A328WN332G BChE. RMSD 
represents the root-mean-square deviation (inA) of the simu-
lated positions of the protein backbone atoms from those in 
the initial structure. The H ... 0 distances in the simulated 
TSl structures corresponding to the wild-type BChE and the 60 
two mutants are summarized in Table 3. The H ... 0 distances 
between the carbonyl oxygen of (-)-cocaine and the peptidic 
NH hydrogen atoms ofG116, G117, andA199 (or S199) of 
BChE are denoted by Dl, D2, and D3, respectively, in Table 
2 and FIG. 1. D4 in Table 3 and FIG. 5 refers to the H ... 0 65 
distance between the carbonyl oxygen of (-)-cocaine and the 
hydroxyl hydrogen of S199 side chain in the simulated TSl 
State 
TS1 for 
(-)-cocaine 
hydrolysis 
catalyzed 
by wild-
type BChE 
TS1 for 
(-)-cocaine 
hydrolysis 
catalyzed 
byA328W/ 
Y332A 
mutant 
TS1 for 
(-)-cocaine 
hydrolysis 
catalyzed by 
A199S/ 
A328W/ 
MD 
MD 
MD 
Method D1 
Average 4.59 
Maximwn 5.73 
Minimum 3.35 
Fluctnation 0.35 
QM/MM 4.10 
Average 3.62 
Maximwn 4.35 
Minimum 2.92 
Fluctnation 0.23 
QM/MM 3.39 
Average 5.30 
Maximwn 6.08 
Minimum 4.57 
Fluctnation 0.22 
QM/MM 4.83 
D2 D3 D4 HBEb 
2.91 1.92 -5.5 (-4.6) 
4.14 2.35 
1.97 1.61 
0.35 0.12 
2.21 2.05 -4.2 
2.35 1.95 -6.2 (-4.9) 
3.37 3.02 
1.78 1.61 
0.27 0.17 
2.05 2.47 -3.3 
2.21 1.94 2.15 -9.7 (-7.4) 
3.06 2.47 3.27 
1.71 1.66 1.56 
0.20 0.13 0.29 
2.09 1.91 2.59 -7.46 
"Dl, D2, and D3 represent the internuclear distances between the carbonyl oxygen of 
cocaine benzoyl ester and the NHhydrogen ofresidues#116 (i.e., G116), #117 (i.e., G117), 
and #119 (i.e.,A199 or S 199) ofBChE, respectively. D4 is the internuclear distance between 
the carbonyl oxygen of cocaine benzoyl ester and the hydroxyl hydrogen ofS 199 side chain 
in the A199S/A328W/Y332G mutant. 
bTbe total HBE value under MD is the average of the HBE values calculated by using the 
instantaneous distances in all of the snapshots. The value in the parenthesis is the total HBE 
value calculated by using the MD-simulated average distances. The total HBE value under 
QM!MM was evaluated by using the QM!MM-optimized distances. 
As seen in Table 3, the simulated H ... 0 distance Dl is 
always too long for the peptidic NH of G 116 to form a 
N-H ... 0 hydrogen bond with the carbonyl oxygen of 
(-)-cocaine. In the simulated TSl structure corresponding to 
wild-type BChE, the carbonyl oxygen of (-)-cocaine formed 
a firm N-H ... 0 hydrogen bond with the peptidic NH 
hydrogen atom of A199 residue; the simulated H ... 0 
distance was 1.61 to 2.35 A, with an average value of 1.92 A. 
Meanwhile, the carbonyl oxygen of (-)-cocaine also had a 
partial N-H ... 0 hydrogen bond with the peptidic NH 
hydrogen atom of G 117 residue; the simulated H . . . 0 
distance was 1.97 to 4.14 A (the average value: 2.91 A). In the 
simulated TS 1 structure corresponding to theA328W N332A 
mutant, the simulated average H ... 0 distances with the 
peptidic NH hydrogen ofG 117 andA199 are 2.35 and 1.95 A, 
respectively. These distances suggest a slightly weaker 
N-H ... 0 hydrogen bond with A199, but a stronger 
N-H ... 0 hydrogen bond with G117, in the simulated TSl 
structure corresponding to the A328W/Y332A mutant. The 
overall strength of the hydrogen bonding between the carbo-
nyl oxygen of (-)-cocaine and the oxyanion hole of the 
enzyme is not expected to change considerably when wild-
type BChE is replaced by the A328W/Y332A mutant. 
However, the story for the simulated TSl structure associ-
ated with theA199S/A328W/Y332G mutant was remarkably 
different. As one can see from Scheme 4, FIG. 5, and Table 3, 
when residue #199 becomes a serine (i.e., S199), the 
hydroxyl group on the side chain ofS199 can also hydrogen-
bond to the carbonyl oxygen of (-)-cocaine to form an 
0-H . . . 0 hydrogen bond, in addition to the two 
N-H ... 0 hydrogen bonds with the peptidic NH of G 117 
and S 199. The simulated average H ... 0 distances with the 
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peptidic NH hydrogen of G 117, peptidic NH hydrogen of 
S199, and hydroxyl hydrogen of S199 are 2.21, 1.94, and 
2.15 A, respectively. Due to the additional 0-H ... 0 
hydrogen bond, the overall strength of the hydrogen bonding 
with the modified oxyanion hole of A199S/A328WN332G 5 
BChE should be significantly stronger than that of the wild-
type andA328WN332A BChE's. 
To better represent the overall strength of hydrogen bond-
ing between the carbonyl oxygen of (-)-cocaine and the oxya-
nion hole in a MD-simulated TS1 structure, the hydrogen 10 
bonding energy (HBE) associated with each simulated 
H ... 0 distance was estimated by using the empirical HBE 
equation implemented in AutoDock 3.0 program suite in 
accordance with (a) Morris, G. M.; Goodsell, D. S.; Halliday, 
R. S.; Huey, R.; Hart, W. E.; Belew. R. K.; Olson, A. J. J. 15 
Comput. Chern. 1998, 19, 1639-1662, and based on the gen-
eral HBE equation, HBE(r),.,5Er0 12 /r12 -6Er0 10 /r10 , in which r 
is the H ... 0 distance in the considered hydrogen bond and 
r0 is the minimum value of the H ... 0 distance for which the 
HBE equation can be used. For the calculation, r0=1.52 A, 20 
because it is the shortest H ... 0 distance found in all of our 
38 
defined TS1 geometry associated with a first-order saddle 
point on the potential energy surface, particularly for the 
hydrogen bonding between the carbonyl oxygen of (-)-co-
caine and the oxyanion hole of BChE. 
The QM/MM results summarized in Table 3 demonstrate 
two hydrogen bonds in each of the QM/MM-optimized TS1 
structures. Specifically, D2=2.21 A and D3=2.05 A in the 
optimized TS1 structure for wild-type BChE; D2=2.05 A and 
D3=2.47 A in the optimized TS1 structure for the A328W/ 
Y332A mutant; D2=2.09 A, D3=1.91 A, and D4=2.59 A in 
the optimized TS1 structure for the A199S/A328WN332G 
mutant. Although the QM/MM-optimized individual H ... 0 
distances and the estimated HBE values are different from the 
corresponding values for individual hydrogen bonds, the rela-
tive total HBE values (i.e., -4.2, -3.3, and -7.46 kcal/mol for 
the wild-type, A328WN332A, and A199S/A328WN332G 
BChE's, respectively) estimated from these optimized dis-
tances are qualitatively consistent with the corresponding 
total HBE values (i.e., -4.6, -4.9, and -7.4 kcal/mol) esti-
mated from the MD-simulated average H ... 0 distances. 
It should be pointed out that the absolute HBE values 
estimated in this study are not expected to be accurate, as 
different computational approaches led different HBE values. 
Nevertheless, for the purpose of our computational design of 
MD simulations. The E value was determined by using the 
condition that HBE(r)=-5.0 kcal/mol when r=1.90 A, herein 
incorporated by reference. Specifically, for each hydrogen 
bond with the carbonyl oxygen of (-)-cocaine, a HBE value 
can be evaluated with each snapshot of the MD-simulated 
structure. The final HBE of the MD-simulated hydrogen bond 
25 a high-activity mutant of BChE, one only needs to know the 
relative strength of the hydrogen bonding based on the esti-
mated relative total HBE values of different mutants. The 
three sets of total HBE values (Table 3) estimated from the is considered to be the average HBE value of all snapshots 
taken from the stable MD trajectory. The estimated total HBE 
value for the hydrogen bonds between the carbonyl oxygen of 30 
(-)-cocaine and the oxyanion hole in each simulated TS 1 
structure is given in Table 3. 
The HBE for each hydrogen bond was estimated by using 
the MD-simulated average H ... 0 distance. As seen in Table 
3, the total hydrogen-bonding energies (i.e., -4.6, -4.9, and 35 
-7.4 kcal/mol for the wild-type,A328WN332A, andA199S/ 
A328WN332G BChE's, respectively) estimated in this way 
are systematically higher (i.e., less negative) than the corre-
sponding total hydrogen-bonding energies (i.e., -5.5, -6.2, 
and -9.7 kcal/mol) estimated in the aforementioned way. 40 
However, the two sets of total HBE values are qualitatively 
consistent in terms of the relative hydrogen-bonding 
strengths in the three simulated TS 1 structures. In particular, 
the two sets of total HBE values consistently reveal that the 
overall strength of the hydrogen bonding between the carbo- 45 
nyl oxygen of (-)-cocaine and the oxyanion hole in the simu-
lated TS1 structure for A199S/A328WN332G BChE is sig-
nificantly higher than that for the wild-type and A328W/ 
Y332A BChE's. 
MD-simulated and QM/MM-optimized H ... 0 distances all 
consistently demonstrate: (1) the overall strength ofhydrogen 
bonding between the carbonyl oxygen of (-)-cocaine and the 
oxyanion hole in the TS 1 structure for (-)-cocaine hydrolysis 
catalyzed by A328W N332A BChE should be close to that in 
the TS1 structure for (-)-cocaine hydrolysis catalyzed by 
wild-type BChE; (2) the overall hydrogen bonding between 
the carbonyl oxygen of (-)-cocaine and the oxyanion hole in 
the TS1 structure for (-)-cocaine hydrolysis catalyzed by 
A199S/A328WN332G BChE should be significantly stron-
ger than that in the TS 1 structure for (-)-cocaine hydrolysis 
catalyzed by A328WN332A BChE. 
Catalytic Activity. 
The computational results discussed above suggest that the 
transition state for the first chemical reaction step (TS1) of 
(-)-cocaine hydrolysis catalyzed by the A199S/A328W/ 
Y332G mutant should be significantly more stable than that 
by theA328WN332A mutant, due to the significant increase 
of the overall hydrogen bonding between the carbonyl oxy-
gen of (-)-cocaine and the oxyanion hole of the enzyme in the 
TS1 structure. The aforementioned analysis of the literature, 
Hydrogen Bonding Based on the QM/MM Calculations. 
The above conclusion obtained from the MD simulations 
was further examined by carrying out QM/MM calculations. 
Although this enzymatic reaction system is too large to cal-
culate the QM/MM force constant matrix required in the 
automated search for a first-order saddle point corresponding 
50 namely Sun et a! and Hamza et a!, also indicate that the first 
chemical reaction step associated with TS1 should be the 
rate-determining step of (-)-cocaine hydrolysis catalyzed by 
a BChE mutant including Y332A or Y332G mutation, 
although the formation of the prereactive enzyme-substrate 
55 complex (ES) is the rate-determining step for (-)-cocaine 
hydrolysis catalyzed by wild-type BChE. This provides evi-
dence of a clear correlation between the TS 1 stabilization and 
the catalytic activity ofA328WN332A andA199S/A328W/ 
Y332G BChE's for (-)-cocaine hydrolysis: the more stable 
to TS1, a partial geometry optimization was performed by 
fixing the length of the transition C-O bond between the 
carbonyl carbon of (-)-cocaine and the QY atom ofS 198 in the 
QM/MM calculation. This transition C-O bond length 
dominates the reaction coordinate, according to the previous 
first-principle reaction coordinate calculations, in accordance 
with Zhan eta!, with an active model of wild-type BChE. In 
the partial geometry optimization, the transition C-O bond 
length was fixed at that in the TS 1 geometry optimized pre-
viously by performing the first-principle reaction coordinate 65 
calculation with an active site model of wild-type BChE. This 
partially optimized geometry should be close to the precisely 
60 the TS 1 structure, the lower the energy barrier, and the higher 
the catalytic activity. Thus, both the MD simulations and 
QM/MM calculations predict that A199S/A328WN332G 
BChE should have a higher catalytic activity than A328W I 
Y332A BChE for (-)-cocaine hydrolysis. 
The catalytic efficiency (kcaiKM) of A328WN332A 
BChE for (-)-cocaine hydrolysis was reported by Sun eta! to 
be -8.6x106 M min-r, which is -9.4 times of the kcaiKM 
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value (-9.1xl05 M min- 1 ) of wild-type BChE. To examine 
the theoretical prediction of the higher catalytic activity for 
A199S/A328WN332G BChE, A328WN332A andA199S/ 
A328WN332G mutants of BChE were produced through 
site-directed mutagenesis. To minimize the possible system- 5 
atic experimental errors of the kinetic data, kinetic studies 
were performed with the two mutants and wild-type BChE 
under the same condition and compared the catalytic effi-
ciency of A328WN332A and A199S/A328WN332G 
BChE's to that of the wild-type for (-)-cocaine hydrolysis at 10 
benzoyl ester group. Based on the kinetic analysis of the 
measured time-dependent radiometric data and the ELISA 
data, the ratio of the kcaiKM value of A328WN332A BChE 
to the kca/KM value of wild-type BChE for (-)-cocaine 15 
hydrolysis was determined to be -8.6. The determined cata-
lytic efficiency ratio of -8.6 is in good agreement with the 
ratio of -9.4 determined by Sun eta!. Further, by using the 
same experimental protocol, the ratio of the kca/KM value of 
A199S/A328WN332G BChE to the kca/KM value of 20 
A328W N332A BChE for (-)-cocaine hydrolysis was deter-
mined to be -7 .2. These data indicate that the ratio of the 
kca/KM value of A199S/A328WN332G BChE to the kca/ 
KM value of wild-type BChE for (-)-cocaine hydrolysis 
should be -7.2x8.6=-62 or -7.2x9.4=-68. Thus, A199S/ 25 
A328W N332G BChE has a-( 65±6)-fold improved catalytic 
efficiency against (-)-cocaine compared to the wild-type, or 
A199S/A328WN332G BChE has a kca/KM value of 
-(5.9±0.5)xl 07 M min- 1 for (-)-cocaine hydrolysis. 
Very recently reported F227A/S287G/A328WN332M 30 
BChE (i.e.,AME-359, kca/KM=3.1xl07 Mmin- 1) has a -34-
fold improved catalytic efficiency for (-)-cocaine hydrolysis. 
AME-359 has the highest catalytic efficiency against (-)-
cocaine within all of the BChE mutants reported in literature 
prior to the present study. The catalytic efficiency for our 35 
A199S/A328WN332G BChE is about two times of that for 
AME-359 against (-)-cocaine. 
Conclusion. 
40 
tion-state modeling is a promising approach for rational 
design of high-activity mutants of BChE as a therapeutic 
treatment of cocaine abuse. 
Experiment 3 
MD Simulation and Generation of Mutant 
A199S/S287G/A328WN332G BChE (Mutant 3) 
(SEQ ID NO: 14) 
The following simulation and mutant generation relate to 
A199S/S287G/A328WN332G (mutant 3) as a rational 
design of a high-activity mutant ofBChE against (-)-cocaine 
based on detailed computational modeling of the transition 
state for the rate-determining step (i.e., the first step of the 
chemical reaction process). Molecular dynamics (MD) simu-
lations were performed to model the protein environmental 
effects on the stabilization of the transition-state structure for 
BChE-catalyzed hydrolysis of (-)-cocaine as described 
above for mutant A199S/A328WN332G (mutant 1). The 
simulated results indicate that the transition-state structure 
can be stabilized much better by the protein environment in 
A199S/S287G/A328WN332G BChE than that in wild-type 
BChE and in other BChE mutants examined. The computa-
tional modeling led to a prediction of the higher catalytic 
efficiency for the A199S/S287G/A328WN332G mutant 
against (-)-cocaine. The prediction has been confirmed by 
wet experimental tests showing that the A199S/S287G/ 
A328W/Y332G mutant has a remarkably improved catalytic 
efficiency against (-)-cocaine. All of the obtained results 
clearly demonstrate that directly modeling the transition-state 
structure provides a reliable computational approach to the 
rational design of a high-activity mutant of BChE against 
(-)-cocaine. 
MD Simulations. 
As with the A199S/A328WN332G mutant, when per-
forming any MD simulation on a transition state, in principle, 
MD simulation using a classical force field (molecular 
mechanics) can only simulate a stable structure correspond-
ing to a local minimum on the potential energy surface, 
whereas a transition state during a reaction process is always 
40 associated with a first-order saddle point on the potential 
energy surface. 
Molecular dynamics (MD) simulations and hybrid quan-
tum mechanical/molecular mechanical (QM/MM) calcula-
tions on the transition state for the first chemical reaction step 
(TS 1) of (-)-cocaine hydrolysis catalyzed by butyryl cho-
linesterase (BChE) mutants lead to a better understanding of 
the effects of protein environment on the transition state sta-
bilization. All of the computational results consistently dem- 45 
onstrate that the overall hydrogen bonding between the car-
bonyl oxygen of (-)-cocaine benzoyl ester and the oxyanion 
hole of BChE in the TS 1 structure for (-)-cocaine hydrolysis 
catalyzed by A199S/A328WN332G BChE should be signifi-
cantly stronger than that in the TS 1 structure for (-)-cocaine 50 
hydrolysis catalyzed by the wild-type and A328WN332A 
BChE's. Thus, both the MD simulations and QM/MM calcu-
lations predict that A199S/A328WN332G BChE should 
have a lower energy barrier for the chemical reaction process 
and, therefore, a higher catalytic efficiency (kca/KM) for (-)- 55 
cocaine hydrolysis; A328WN332A BChE has been known 
to have a -9-fold improved catalytic efficiency for (-)-co-
caine hydrolysis. The theoretical prediction has been con-
firmed by wet experimental tests showing a -(65±6)-fold 
improved catalytic efficiency for A199S/A328WN332G 60 
BChE against (-)-cocaine compared to the wild-type BChE. 
The kca/KM value determined for A199S/A328WN332G 
BChE is about two times of the kcaiKM value for F227 AI 
S287G/A328WN332M BChE (i.e., AME-359, which has 
the highest catalytic efficiency within all BChE mutants 65 
reported prior to the present study) against (-)-cocaine. The 
encouraging outcome of this study suggests that the transi-
The initial BChE structures used in the MD simulations 
were prepared based on our previous MD simulation as above 
with the prior mutant and the prereactive BChE-(-)-cocaine 
complex (ES) started from the X-ray crystal structure depos-
ited in the Protein Data Bank (pdb code: !POP). 
The general procedure for carrying out the MD simulations 
in water is essentially the same as that used in the computa-
tional studies for mutantA199S/A328WN332G (mutant 1). 
Site-directed mutagenesis of human BChE eDNA was per-
formed as described before. 
The MD simulation in water was performed as described 
above, on this mutant. Depicted in FIG. 6 are plots of four 
important H ... 0 distances in the MD-simulated TSl struc-
ture versus the simulation time for (-)-cocaine hydrolysis 
catalyzed by A199S/S287G/A328WN332G BChE, along 
with the root-mean-square deviation (RMSD) of the simu-
lated positions of backbone atoms from those in the corre-
sponding initial structure. Traces D 1, D2, and D3 refer to the 
distances between the carbonyl oxygen of (-)-cocaine and the 
NH hydrogen ofG116, G117, and S199, respectively. Trace 
D4 is the internuclear distance between the carbonyl oxygen 
of (-)-cocaine and the hydroxyl hydrogen of the S 199 side 
chain in A199S/S287G/A328WN332G BChE (mutant 3). 
RMSD represents the root-mean-square deviation (in A) of 
the simulated positions of the protein backbone atoms from 
those in the initial structure. 
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The H ... 0 distances in the simulated TS 1 structures for 
wild-type BChE and its three mutants are summarized in 
Table 4. The H ... 0 distances between the carbonyl oxygen 
of (-)-cocaine and the peptidic NH hydrogen atoms of G 116, 
G117, andA199 (or S199) ofBChE are denoted by Dl, D2, 
and D3, respectively, in Table 4 and FIG. 6. D4 in Table 4 and 
FIG. 6 refers to the H ... 0 distance between the carbonyl 
oxygen of (-)-cocaine and the hydroxyl hydrogen of S 199 
side chain in the simulated TS 1 structure corresponding to the 
A199S/S287G/A328W/Y332G mutant. 
Table 4. Summary of the MD-simulated key distances (in 
A) and the calculated total hydrogen-bonding energies (HBE, 
in kcal/mol) between the oxyanion hole and the carbonyl 
oxygen of (-)-cocaine benzoyl ester in the first transition state 
(TS1). 
Distancea Total 
Transition State D1 D2 D3 D4 HBEb 
TS 1 structure for Average 4.59 2.91 1.92 -5.5 
(-)-cocaine (-4.6) 
hydrolysis catalyzed Maximum 5.73 4.14 2.35 
by wild-type Minimum 3.35 1.97 1.61 
Fluctnation 0.35 0.35 0.12 
TS 1 structure for Average 3.62 2.35 1.95 -6.2 
(-)-cocaine (-4.9) 
hydrolysis catalyzed Maximum 4.35 3.37 3.02 
by Minimum 2.92 1.78 1.61 
Fluctnation 0.23 0.27 0.17 
TS 1 structure for Average 3.60 2.25 1.97 -6.4 
(-)-cocaine (-5.0) 
hydrolysis catalyzed Maximum 4.24 3.17 2.76 
by A328W/Y332G Minimum 2.89 1.77 1.62 
mutant ofBChE Fluctnation 0.23 0.24 0.17 
TS 1 structure for Average 4.39 2.60 2.01 1.76 -14.0 
(-)-cocaine (-12.0) 
hydrolysis catalyzed Maximum 5.72 4.42 2.68 2.50 
by A199S/S287G/ Minimum 2.87 1.76 1.62 1.48 
A328W/Y332G Fluctnation 0.48 0.36 0.17 0.12 
aDl, D2, and D3 represent the internuclear distances between the carbonyl oxygen of 
cocaine benzoyl ester and the NHhydrogen of residues #116 (i.e., G116), #117 (i.e., G117), 
and#l19 (i.e.,A199 or S199) ofBChE,respectively. D4is the internuclear distance between 
the carbonyl oxygen of cocaine benzoyl ester and the hydroxyl hydrogen ofS 199 side chain 
in the A199S/A328W/Y332G mutant. 
bTbe total HBE value under MD is the average of the HBE values calculated by using the 
instantaneous distances in all of the snapshots. The value in the parenthesis is the total HBE 
value calculated by using the MD-simulated average distances. The total HBE value under 
QM!MM was evaluated by using the QM!MM-optimized distances. 
42 
As seen in Table 4, the simulated H ... 0 distance D1 is 
always too long for the peptidic NH of G 116 to form a 
N-H ... 0 hydrogen bond with the carbonyl oxygen of 
(-)-cocaine in all of the simulated TS 1 structures. In the 
simulated TS1 structure for wild-type BChE, the carbonyl 
oxygen of (-)-cocaine formed a firm N-H ... 0 hydrogen 
bond with the peptidic NH hydrogen atom of A199 residue; 
the simulated H ... 0 distance (D2) was 1.61 to 2.35 A, with 
an average D2 value of 1.92 A. Meanwhile, the carbonyl 
10 
oxygen of (-)-cocaine also had a partial N-H ... 0 hydrogen 
bond with the peptidic NH hydrogen atom of G 117 residue; 
the simulated H ... 0 distance (D3) was 1.97 to 4.14 A (the 
average D3 value: 2.91 A). The average D2 and D3 values 
became 2.35 and 1.95 A, respectively, in the simulated TS1 
15 structure for the A328W/Y332A mutant. These distances 
20 
25 
30 
35 
40 
suggest a slightly weaker N-H ... 0 hydrogen bond with 
A199, but a stronger N-H ... 0 hydrogen bond with G 117, 
in the simulated TS1 structure for theA328W /Y332A mutant 
that the corresponding N-H ... 0 hydrogen bonds for the 
wild-type. The average D2 and D3 values (2.25 and 1.97 A, 
respectively) in the simulated TS1 structure for the A328W/ 
Y332G mutant are close to the corresponding distances for 
theA328W/Y332Amutant. The overall strength of the hydro-
gen bonding between the carbonyl oxygen of (-)-cocaine and 
the oxyanion hole of the enzyme is not expected to change 
considerably when wild-type BChE is replaced by the 
A328W/Y332A or A328W/Y332G mutant. 
However, the story for the simulated TS 1 structure for the 
A199S/S287G/A328W/Y332G mutant was remarkably dif-
ferent. As one can see from Scheme 5, FIG. 6, and Table 4, 
when residue #199 becomes a serine (i.e., S199), the 
hydroxyl group on the side chain ofS199 can also hydrogen-
bond to the carbonyl oxygen of (-)-cocaine to form an 
0-H . . . 0 hydrogen bond, in addition to the two 
N-H ... 0 hydrogen bonds with the peptidic NH of G 117 
and S 199. The simulated average H ... 0 distances with the 
peptidic NH hydrogen of G 117, peptidic NH hydrogen of 
S199, and hydroxyl hydrogen of S199 are 2.60, 2.01, and 
1.76 A, respectively. Due to the additional 0-H ... 0 
hydrogen bond, the overall strength of the hydrogen bonding 
with the modified oxyanion hole of A199S/S287G/A328W/ 
Y332G BChE should be significantly stronger than that of 
wild-type, A328W/Y332A, andA328W/Y332G BChE's. 
Scheme 5. Schematic representation of the transition-state structure for first reaction 
step for(- )-cocaine hydrolysis catalyzed by a BChE mutant with an A199S mutation. 
Gly116-N-H 
I 
Gly117-N-H 
CH2-0-H 
I 
Ser199-C-N-H 
H 
His438 0 
OCH
3 ~N---H---~AGlu325 
H---N::::,.._ / 
o ____ _.o~--- ~ 
El ~.-----0=-=-::C 6 '""" 
US 9,206,403 Bl 
43 
To better represent the overall strength of hydrogen bond-
ing between the carbonyl oxygen of (-)-cocaine and the oxya-
nion hole in a MD-simulated TS1 structure, the hydrogen 
bonding energy (HBE) associated with each simulated 
H ... 0 distance was estimated by using the empirical HBE 5 
equation implemented in Auto Dock 3.0 program suite of (a) 
Masson, P.; Legrand, P.; Bartels, C. F.; Froment, M.-T.; 
Schopfer, L. M.; Lockridge, 0. Biochemistry 1997, 36, 2266, 
(b) Masson, P.; Xie, W., Froment, M-T.; Levitsky, V.; Fortier, 
P.-L.; Albaret, C.; Lockridge, 0. Biochim. Biophys. Acta 10 
1999, 1433,281, (c) Xie, W.;Altamirano, C. V.; Bartels, C. F.; 
Speirs, R. J.; Cashman, J. R.; Lockridge, 0. Mol. Pharmacal. 
1999, 55, 83, (d) Duysen, E. G.; Bartels, C. F.; Lockridge, 0. 
J. Pharmacal. Exp. Ther. 2002, 302, 751, (e) Nachon, F.; 15 
Nicolet, Y.; Viguie, N.; Masson, P.; Fontecilla-Camps, J. C.; 
Lockridge, 0. Eur. J. Biochem. 2002, 269, 630, herein all 
incorporated by reference. Specifically, for each hydrogen 
bond with the carbonyl oxygen of (-)-cocaine, a HBE value 
can be evaluated with each snapshot of the MD-simulated 20 
structure. The final HBE of the MD-simulated hydrogen bond 
is considered to be the average HBE value of all snapshots 
taken from the stable MD trajectory. The estimated total HBE 
value for the hydrogen bonds between the carbonyl oxygen of 
(-)-cocaine and the oxyanion hole in each simulated TS 1 25 
structure is also listed in Table 4. 
The HBE for each hydrogen bond was estimated by using 
the MD-simulated average H ... 0 distance. As seen in Table 
4, the total hydrogen-bonding energies (i.e., -4.6, -4.9, -5.0, 
and -12.0 kcal/mol for the wild-type, A328W/Y332A, 30 
A328W/Y332G, and A199S/S287G/A328W/Y332G 
BChE's, respectively) estimated in this way are systemati-
cally higher (i.e., less negative) than the corresponding total 
hydrogen-bonding energies (i.e., -5.5, -6.2, -6.4, and -14.0 
kcal/mol) estimated in the aforementioned way. However, the 35 
two sets of total HBE values are qualitatively consistent with 
each other in terms of the relative hydrogen-bonding 
strengths in the three simulated TS 1 structures. In particular, 
the two sets of total HBE values consistently reveal that the 
overall strength of the hydrogen bonding between the carbo- 40 
nyl oxygen of (-)-cocaine and the oxyanion hole in the simu-
lated TS1 structure for A199S/S287G/A328W/Y332G BChE 
is significantly higher than that for wild-type, A328W/ 
Y332A, andA328W/Y332G BChE's. 
Catalytic Activity. 45 
The computational results discussed above provides evi-
dence that the transition state for the first chemical reaction 
step (TS1) of(-)-cocaine hydrolysis catalyzed by theA199S/ 
S287G/A328W/Y332G mutant should be significantly more 
stable than that by the A328W/Y332A or A328W/Y332G 50 
mutant, due to the significant increase of the overall hydrogen 
bonding between the carbonyl oxygen of (-)-cocaine and the 
oxyanion hole of the enzyme in the TS 1 structure. The afore-
mentioned analysis of the literature of Sun eta! and Hamza et 
a! also indicates that the first chemical reaction step associ- 55 
ated with TS1 should be the rate-determining step of (-)-
cocaine hydrolysis catalyzed by a BChE mutant including 
Y332A or Y332G mutation, although the formation of the 
prereactive enzyme-substrate complex (ES) is the rate-deter-
mining step for (-)-cocaine hydrolysis catalyzed by wild- 60 
type BChE. This suggests a clear correlation between the TS 1 
stabilization and the catalytic activity of A328W/Y332A, 
A328W/Y332G, and A199S/S287G/A328W/Y332G 
BChE's for (-)-cocaine hydrolysis: the more stable the TS1 
structure, the lower the energy barrier, and the higher the 65 
catalytic activity. Thus, the MD simulations predict that 
A199S/S287G/A328W/Y332G BChE should have a higher 
44 
catalytic activity than A328W/Y332A or A328W/Y332G 
BChE for (-)-cocaine hydrolysis. 
The catalytic efficiency (kcaiKM) of A328W/Y332A 
BChE for (-)-cocaine hydrolysis was reported to be -8.6x1 06 
M min- 1 , which is -9.4 times of the kcaiKM value (-9.1x105 
M min- 1) of wild-type BChE for (-)-cocaine hydrolysis. The 
catalytic efficiency ofA328W/Y332G BChE was found to be 
slightly higher than that of A328W/Y332A BChE for (-)-
cocaine hydrolysis. To examine the theoretical prediction of 
the higher catalytic activity for A199S/S287G/A328W/ 
Y332G BChE, the A328W/Y332A and A199S/S287G/ 
A328W/Y332G mutants of BChE were produced as previ-
ously discussed through site-directed mutagenesis. To 
minimize the possible systematic experimental errors of the 
kinetic data, kinetic studies were performed with the two 
mutants and wild-type BChE under the same condition and 
compared the catalytic efficiency of A328W/Y332A and 
A199S/S287G/A328W/Y332G BChE's to that of the wild-
type for (-)-cocaine hydrolysis at benzoyl ester group. Based 
on the kinetic analysis of the measured time-dependent radio-
metric data and the ELISA data, the ratio of the kcaiKM value 
of A328W/Y332A BChE to the kcaiKM value of wild-type 
BChE for (-)-cocaine hydrolysis was determined to be -8.6. 
The determined catalytic efficiency ratio of -8.6 is in good 
agreement with the ratio of -9.4 determined by Sun et a!. 
Further, by using the same experimental protocol, the ratio of 
thekca/KMvalue ofA199S/S287G/A328W/Y332G BChE to 
the kcaiKM value of A328W /Y332A BChE for (-)-cocaine 
hydrolysis was determined to be -50.6. These data indicate 
that the ratio of the kcaiKM value of A199S/S287G/ A328W I 
Y332G BChE to the kcaiKM value of wild-type BChE for 
(-)-cocaine hydrolysis should be -50.6x8.6=-435 or -50.6x 
9 .4=-4 7 6. Thus, A199S/S287G/ A328W /Y332G BChE has a 
-( 456±41 )-fold improved catalytic efficiency against (-)-co-
caine compared to the wild-type, or A199S/S287G/A328W/ 
Y332G BChE has a kcaiKMvalue of -(4.15±0.37)x108 M 
min- 1 for (-)-cocaine hydrolysis. The catalytic efficiency of 
A199S/S287G/ A328W /Y332G BChE against (-)-cocaine is 
much higher than that of AME-359 (i.e., F227A/S287G/ 
A328W/Y332M BChE, kca/KM=3.1x107 M min, whose 
catalytic efficiency against (-)-cocaine is the highest within 
all of the previously reported BChE mutants) which has a 
-34-fold improved catalytic efficiency against (-)-cocaine 
compared to wild-type BChE. 
By using the designed A199S/S287G/A328W/Y332G 
BChE as an exogenous enzyme in human, when the concen-
tration of this mutant is kept the same as that of the wild-type 
BChE in plasma, the half-life time of (-)-cocaine in plasma 
should be reduced from the -45-90 min to only -6-12 sec-
onds, considerably shorter than the time required for cocaine 
crossing the blood-brain barrier to reach CNS. Hence, the 
outcome of this study could eventually result in a valuable, 
efficient anti-cocaine medication. 
Conclusion. 
The transition-state simulations demonstrate that the over-
all hydrogen bonding between the carbonyl oxygen of (-)-
cocaine benzoyl ester and the oxyanion hole of BChE in the 
TS 1 structure for (-)-cocaine hydrolysis catalyzed by A199S/ 
S287G/A328W/Y332G BChE should be significantly stron-
ger than that in the TS 1 structure for (-)-cocaine hydrolysis 
catalyzed by the wild-type BChE and other BChE mutants 
simulated. Thus, the MD simulations predict that A199S/ 
S287G/A328W/Y332G BChE should have a significantly 
lower energy barrier for the chemical reaction process and, 
therefore, a significantly higher catalytic efficiency (kcaiKM) 
for (-)-cocaine hydrolysis. The theoretical prediction has 
been confirmed by wet experimental tests showing a 
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-(456±41)-fold improved catalytic efficiency for A199S/ 
S287G/A328WN332G BChE against (-)-cocaine compared 
to the wild-type BChE. The kcaiKM value determined for 
A199S/S287G/A328WN332G BChE is much higher than 
thekca/KMvalueforAME-359 (i.e., F227A/S287G/A328W/ 
Y332M BChE, whose catalytic efficiency against (-)-cocaine 
is the highest within all of the BChE mutants reported previ-
ously in literature) which has a -34-fold improved catalytic 
efficiency against (-)-cocaine compared to the wild-type 
BChE. The outcome of this study provides evidence that the 
transition-state simulation is a novel and unique approach for 
rational enzyme redesign and drug discovery. 
<160> NUMBER OF SEQ ID NOS, 30 
<210> SEQ ID NO 1 
<211> LENGTH, 1722 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
SEQUENCE LISTING 
Although the invention has been described in detail with 
respect to preferred embodiments thereof, it will be apparent 
that the invention is capable of numerous modifications and 
variations, apparent to those skilled in the art, without depart-
ing from the spirit and scope of the invention. 
<223> OTHER INFORMATION, 14-1 mutant A199S/A328W/Y332G of Human 
butyrylcholinesterase (BChE) 
<400> SEQUENCE, 1 
gaagatgaca tcataattgc aacaaagaat ggaaaagtca gagggatgaa cttgacagtt 60 
tttggtggca cggtaacagc ctttcttgga attccctatg cacagccacc tcttggtaga 120 
cttcgattca aaaagccaca gtctctgacc aagtggtctg atatttggaa tgccacaaaa 180 
tatgcaaatt cttgctgtca gaacatagat caaagttttc caggcttcca tggatcagag 240 
atgtggaacc caaacactga cctcagtgaa gactgtttat atctaaatgt atggattcca 300 
gcacctaaac caaaaaatgc cactgtattg atatggattt atggtggtgg ttttcaaact 360 
ggaacatcat ctttacatgt ttatgatggc aagtttctgg ctcgggttga aagagttatt 420 
gtagtgtcaa tgaactatag ggtgggtgcc ctaggattct tagctttgcc aggaaatcct 480 
gaggctccag ggaacatggg tttatttgat caacagttgg ctcttcagtg ggttcaaaaa 540 
aatatagcag cctttggtgg aaatcctaaa agtgtaactc tctttggaga aagttccgga 600 
gcagcttcag ttagcctgca tttgctttct cctggaagcc attcattgtt caccagagcc 660 
attctgcaaa gtggttcctt taatgctcct tgggcggtaa catctcttta tgaagctagg 720 
aacagaacgt tgaacttagc taaattgact ggttgctcta gagagaatga gactgaaata 780 
atcaagtgtc ttagaaataa agatccccaa gaaattcttc tgaatgaagc atttgttgtc 840 
ccctatggga ctcctttgtc agtaaacttt ggtccgaccg tggatggtga ttttctcact 900 
gacatgccag acatattact tgaacttgga caatttaaaa aaacccagat tttggtgggt 960 
gttaataaag atgaagggac atggttttta gtcggtggtg ctcctggctt cagcaaagat 1020 
aacaatagta tcataactag aaaagaattt caggaaggtt taaaaatatt ttttccagga 1080 
gtgagtgagt ttggaaagga atccatcctt tttcattaca cagactgggt agatgatcag 1140 
agacctgaaa actaccgtga ggccttgggt gatgttgttg gggattataa tttcatatgc 1200 
cctgccttgg agttcaccaa gaagttctca gaatggggaa ataatgcctt tttctactat 1260 
tttgaacacc gatcctccaa acttccgtgg ccagaatgga tgggagtgat gcatggctat 1320 
gaaattgaat ttgtctttgg tttacctctg gaaagaagag ataattacac aaaagccgag 1380 
gaaattttga gtagatccat agtgaaacgg tgggcaaatt ttgcaaaata tgggaatcca 1440 
aatgagactc agaacaatag cacaagctgg cctgtcttca aaagcactga acaaaaatat 1500 
ctaaccttga atacagagtc aacaagaata atgacgaaac tacgtgctca acaatgtcga 1560 
ttctggacat cattttttcc aaaagtcttg gaaatgacag gaaatattga tgaagcagaa 1620 
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tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa 
tttaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc 
<210> SEQ ID NO 2 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 14-1 mutant (A199S/A328W/Y332G) amino acid 
sequence modified BChE 
<400> SEQUENCE, 2 
Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met 
1 5 10 15 
Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro 
20 25 30 
Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 
35 40 45 
Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser 
50 55 60 
Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu 
65 70 75 80 
Met Trp Asn Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn 
85 90 95 
Val Trp Ile Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp 
100 105 110 
Ile Tyr Gly Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr 
115 120 125 
Asp Gly Lys Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met 
130 135 140 
Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro 
145 150 155 160 
Glu Ala Pro Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln 
165 170 175 
Trp Val Gln Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val 
180 185 190 
Thr Leu Phe Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu 
195 200 205 
Leu Ser Pro Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser 
210 215 220 
Gly Ser Phe Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg 
225 230 235 240 
Asn Arg Thr Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn 
245 250 255 
Glu Thr Glu Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile 
260 265 270 
Leu Leu Asn Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Ser Val 
275 280 285 
Asn Phe Gly Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp 
290 295 300 
Ile Leu Leu Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly 
305 310 315 320 
Val Asn Lys Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly 
325 330 335 
Phe Ser Lys Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu 
48 
1680 
1722 
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340 345 350 
Gly Leu Lys Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser 
355 360 365 
Ile Leu Phe His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn 
370 375 380 
Tyr Arg Glu Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys 
385 390 395 400 
Pro Ala Leu Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala 
405 410 415 
Phe Phe Tyr Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu 
420 425 430 
Trp Met Gly Val Met His Gly Tyr Glu Ile Glu Phe Val Phe Gly Leu 
435 440 445 
Pro Leu Glu Arg Arg Asp Asn Tyr Thr Lys Ala Glu Glu Ile Leu Ser 
450 455 460 
Arg Ser Ile Val Lys Arg Trp Ala Asn Phe Ala Lys Tyr Gly Asn Pro 
465 470 475 480 
Asn Glu Thr Gln Asn Asn Ser Thr Ser Trp Pro Val Phe Lys Ser Thr 
485 490 495 
Glu Gln Lys Tyr Leu Thr Leu Asn Thr Glu Ser Thr Arg Ile Met Thr 
500 505 510 
Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys 
515 520 525 
Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys 
530 535 
Ala Gly Phe His Arg Trp Asn Asn Tyr Met 
545 550 
Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser 
565 
<210> SEQ ID NO 3 
<211> LENGTH, 1125 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
570 
540 
Met Asp Trp Lys Asn Gln 
555 560 
Cys Val Gly Leu 
<223> OTHER INFORMATION, truncated 14-1 (A199S/A328/Y332G) nucleic Acid 
Sequence for modified BChE corresponding to a.a. residues 68-442 
<400> SEQUENCE, 3 
aacatagatc aaagttttcc aggcttccat ggatcagaga tgtggaaccc aaacactgac 60 
ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc 120 
actgtattga tatggattta tggtggtggt tttcaaactg gaacatcatc tttacatgtt 180 
tatgatggca agtttctggc tcgggttgaa agagttattg tagtgtcaat gaactatagg 240 
gtgggtgccc taggattctt agctttgcca ggaaatcctg aggctccagg gaacatgggt 300 
ttatttgatc aacagttggc tcttcagtgg gttcaaaaaa atatagcagc ctttggtgga 360 
aatcctaaaa gtgtaactct ctttggagaa agttccggag cagcttcagt tagcctgcat 420 
ttgctttctc ctggaagcca ttcattgttc accagagcca ttctgcaaag tggttccttt 480 
aatgctcctt gggcggtaac atctctttat gaagctagga acagaacgtt gaacttagct 540 
aaattgactg gttgctctag agagaatgag actgaaataa tcaagtgtct tagaaataaa 600 
gatccccaag aaattcttct gaatgaagca tttgttgtcc cctatgggac tcctttgtca 660 
gtaaactttg gtccgaccgt ggatggtgat tttctcactg acatgccaga catattactt 720 
50 
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-continued 
gaacttggac aatttaaaaa aacccagatt ttggtgggtg ttaataaaga tgaagggaca 
tggtttttag tcggtggtgc tcctggcttc agcaaagata acaatagtat cataactaga 
aaagaatttc aggaaggttt aaaaatattt tttccaggag tgagtgagtt tggaaaggaa 
tccatccttt ttcattacac agactgggta gatgatcaga gacctgaaaa ctaccgtgag 
gccttgggtg atgttgttgg ggattataat ttcatatgcc ctgccttgga gttcaccaag 
aagttctcag aatggggaaa taatgccttt ttctactatt ttgaacaccg atcctccaaa 
cttccgtggc cagaatggat gggagtgatg catggctatg aaatt 
<210> SEQ ID NO 4 
<211> LENGTH, 375 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
780 
840 
900 
960 
1020 
1080 
1125 
<223> OTHER INFORMATION, truncated 14-1 mutant (A199S/A328/Y332G) amino 
acid sequence of modified BChE 
<400> SEQUENCE, 4 
Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn 
1 5 10 15 
Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile 
20 25 30 
Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly 
35 40 45 
Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys 
50 55 60 
Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg 
65 70 75 80 
Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro 
85 90 95 
Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln 
100 105 110 
Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe 
115 120 125 
Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro 
130 135 140 
Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Phe 
145 150 155 160 
Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr 
165 170 175 
Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu 
180 185 190 
Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn 
195 200 205 
Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Ser Val Asn Phe Gly 
210 215 220 
Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu 
225 230 235 240 
Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys 
245 250 255 
Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys 
260 265 270 
Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys 
275 280 285 
52 
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Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe 
290 295 300 
His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu 
305 310 315 320 
Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu 
325 330 335 
Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr 
340 345 350 
Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly 
355 360 365 
Val Met His Gly Tyr Glu Ile 
370 375 
<210> SEQ ID NO 5 
<211> LENGTH, 966 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 14-1 mutant (A199S/A328W/Y332G) BChE nucleic 
acid sequence corresponding to a.a. residues 117-438 
<400> SEQUENCE, 5 
ggttttcaaa ctggaacatc atctttacat gtttatgatg gcaagtttct ggctcgggtt 60 
gaaagagtta ttgtagtgtc aatgaactat agggtgggtg ccctaggatt cttagctttg 120 
ccaggaaatc ctgaggctcc agggaacatg ggtttatttg atcaacagtt ggctcttcag 180 
tgggttcaaa aaaatatagc agcctttggt ggaaatccta aaagtgtaac tctctttgga 240 
gaaagttccg gagcagcttc agttagcctg catttgcttt ctcctggaag ccattcattg 300 
ttcaccagag ccattctgca aagtggttcc tttaatgctc cttgggcggt aacatctctt 360 
tatgaagcta ggaacagaac gttgaactta gctaaattga ctggttgctc tagagagaat 420 
gagactgaaa taatcaagtg tcttagaaat aaagatcccc aagaaattct tctgaatgaa 480 
gcatttgttg tcccctatgg gactcctttg tcagtaaact ttggtccgac cgtggatggt 540 
gattttctca ctgacatgcc agacatatta cttgaacttg gacaatttaa aaaaacccag 600 
attttggtgg gtgttaataa agatgaaggg acatggtttt tagtcggtgg tgctcctggc 660 
ttcagcaaag ataacaatag tatcataact agaaaagaat ttcaggaagg tttaaaaata 720 
ttttttccag gagtgagtga gtttggaaag gaatccatcc tttttcatta cacagactgg 780 
gtagatgatc agagacctga aaactaccgt gaggccttgg gtgatgttgt tggggattat 840 
aatttcatat gccctgcctt ggagttcacc aagaagttct cagaatgggg aaataatgcc 900 
tttttctact attttgaaca ccgatcctcc aaacttccgt ggccagaatg gatgggagtg 960 
atgcat 966 
<210> SEQ ID NO 6 
<211> LENGTH, 322 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 14-1 mutant (A199S/A328W/Y332G) BChE a.a. 
residues 117-438 
<400> SEQUENCE, 
Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe 
1 5 10 15 
Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val 
20 25 30 
54 
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Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly 
35 40 45 
Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys 
50 55 60 
Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe Gly 
65 70 75 80 
Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly 
85 90 95 
Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Phe Asn 
100 105 110 
Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu 
115 120 125 
Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile 
130 135 140 
Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn Glu 
145 150 155 160 
Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Ser Val Asn Phe Gly Pro 
165 170 175 
Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu Glu 
180 185 190 
Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys Asp 
195 200 205 
Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys Asp 
210 215 220 
Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys Ile 
225 230 235 240 
Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe His 
245 250 255 
Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu Ala 
260 265 270 
Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu Glu 
275 280 285 
Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr Tyr 
290 295 300 
Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly Val 
305 310 315 320 
Met His 
<210> SEQ ID NO 7 
<211> LENGTH, 1722 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 14-2 mutant (A199S/F227A/A328W/Y332G) BChE, 
full nucleic acid sequence 
<400> SEQUENCE, 7 
gaagatgaca tcataattgc aacaaagaat ggaaaagtca gagggatgaa cttgacagtt 60 
tttggtggca cggtaacagc ctttcttgga attccctatg cacagccacc tcttggtaga 120 
cttcgattca aaaagccaca gtctctgacc aagtggtctg atatttggaa tgccacaaaa 180 
tatgcaaatt cttgctgtca gaacatagat caaagttttc caggcttcca tggatcagag 240 
atgtggaacc caaacactga cctcagtgaa gactgtttat atctaaatgt atggattcca 300 
gcacctaaac caaaaaatgc cactgtattg atatggattt atggtggtgg ttttcaaact 360 
56 
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-continued 
ggaacatcat ctttacatgt ttatgatggc aagtttctgg ctcgggttga aagagttatt 
gtagtgtcaa tgaactatag ggtgggtgcc ctaggattct tagctttgcc aggaaatcct 
gaggctccag ggaacatggg tttatttgat caacagttgg ctcttcagtg ggttcaaaaa 
aatatagcag cctttggtgg aaatcctaaa agtgtaactc tctttggaga aagttccgga 
gcagcttcag ttagcctgca tttgctttct cctggaagcc attcattgtt caccagagcc 
attctgcaaa gtggttccgc taatgctcct tgggcggtaa catctcttta tgaagctagg 
aacagaacgt tgaacttagc taaattgact ggttgctcta gagagaatga gactgaaata 
atcaagtgtc ttagaaataa agatccccaa gaaattcttc tgaatgaagc atttgttgtc 
ccctatggga ctcctttgtc agtaaacttt ggtccgaccg tggatggtga ttttctcact 
gacatgccag acatattact tgaacttgga caatttaaaa aaacccagat tttggtgggt 
gttaataaag atgaagggac atggttttta gtcggtggtg ctcctggctt cagcaaagat 
aacaatagta tcataactag aaaagaattt caggaaggtt taaaaatatt ttttccagga 
gtgagtgagt ttggaaagga atccatcctt tttcattaca cagactgggt agatgatcag 
agacctgaaa actaccgtga ggccttgggt gatgttgttg gggattataa tttcatatgc 
cctgccttgg agttcaccaa gaagttctca gaatggggaa ataatgcctt tttctactat 
tttgaacacc gatcctccaa acttccgtgg ccagaatgga tgggagtgat gcatggctat 
gaaattgaat ttgtctttgg tttacctctg gaaagaagag ataattacac aaaagccgag 
gaaattttga gtagatccat agtgaaacgg tgggcaaatt ttgcaaaata tgggaatcca 
aatgagactc agaacaatag cacaagctgg cctgtcttca aaagcactga acaaaaatat 
ctaaccttga atacagagtc aacaagaata atgacgaaac tacgtgctca acaatgtcga 
ttctggacat cattttttcc aaaagtcttg gaaatgacag gaaatattga tgaagcagaa 
tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa 
tttaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc 
<210> SEQ ID NO 8 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 14-2 mutant (A199S/F227A/A328W/Y332G), full 
amino acid sequence 
<400> SEQUENCE, 8 
Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met 
1 5 10 15 
Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro 
20 25 30 
Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 
35 40 45 
Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser 
50 55 60 
Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu 
65 70 75 80 
Met Trp Asn Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn 
85 90 95 
Val Trp Ile Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp 
100 105 110 
58 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1560 
1620 
1680 
1722 
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Ile Tyr Gly Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr 
115 120 125 
Asp Gly Lys Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met 
130 135 140 
Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro 
145 150 155 160 
Glu Ala Pro Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln 
165 170 175 
Trp Val Gln Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val 
180 185 190 
Thr Leu Phe Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu 
195 200 205 
Leu Ser Pro Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser 
210 215 220 
Gly Ser Ala Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg 
225 230 235 240 
Asn Arg Thr Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn 
245 250 255 
Glu Thr Glu Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile 
260 265 270 
Leu Leu Asn Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Ser Val 
275 280 285 
Asn Phe Gly Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp 
290 295 300 
Ile Leu Leu Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly 
305 310 315 320 
Val Asn Lys Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly 
325 330 335 
Phe Ser Lys Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu 
340 345 350 
Gly Leu Lys Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser 
355 360 365 
Ile Leu Phe His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn 
370 375 380 
Tyr Arg Glu Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys 
385 390 395 400 
Pro Ala Leu Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala 
405 410 415 
Phe Phe Tyr Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu 
420 425 430 
Trp Met Gly Val Met His Gly Tyr Glu Ile Glu Phe Val Phe Gly Leu 
435 440 445 
Pro Leu Glu Arg Arg Asp Asn Tyr Thr Lys Ala Glu Glu Ile Leu Ser 
450 455 460 
Arg Ser Ile Val Lys Arg Trp Ala Asn Phe Ala Lys Tyr Gly Asn Pro 
465 470 475 480 
Asn Glu Thr Gln Asn Asn Ser Thr Ser Trp Pro Val Phe Lys Ser Thr 
485 490 495 
Glu Gln Lys Tyr Leu Thr Leu Asn Thr Glu Ser Thr Arg Ile Met Thr 
500 505 510 
Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys 
515 520 525 
Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys 
60 
US 9,206,403 Bl 
61 
-continued 
530 535 540 
Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 
545 550 555 560 
Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 
565 570 
<210> SEQ ID NO 9 
<211> LENGTH, 1125 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 14-2 mutant (A199/F227A/A328W/Y322G) BChE 
nucleic acid sequence for a.a. residues 68-442 
<400> SEQUENCE, 9 
aacatagatc aaagttttcc aggcttccat ggatcagaga tgtggaaccc aaacactgac 
ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc 
actgtattga tatggattta tggtggtggt tttcaaactg gaacatcatc tttacatgtt 
tatgatggca agtttctggc tcgggttgaa agagttattg tagtgtcaat gaactatagg 
gtgggtgccc taggattctt agctttgcca ggaaatcctg aggctccagg gaacatgggt 
ttatttgatc aacagttggc tcttcagtgg gttcaaaaaa atatagcagc ctttggtgga 
aatcctaaaa gtgtaactct ctttggagaa agttccggag cagcttcagt tagcctgcat 
ttgctttctc ctggaagcca ttcattgttc accagagcca ttctgcaaag tggttccgct 
aatgctcctt gggcggtaac atctctttat gaagctagga acagaacgtt gaacttagct 
aaattgactg gttgctctag agagaatgag actgaaataa tcaagtgtct tagaaataaa 
gatccccaag aaattcttct gaatgaagca tttgttgtcc cctatgggac tcctttgtca 
gtaaactttg gtccgaccgt ggatggtgat tttctcactg acatgccaga catattactt 
gaacttggac aatttaaaaa aacccagatt ttggtgggtg ttaataaaga tgaagggaca 
tggtttttag tcggtggtgc tcctggcttc agcaaagata acaatagtat cataactaga 
aaagaatttc aggaaggttt aaaaatattt tttccaggag tgagtgagtt tggaaaggaa 
tccatccttt ttcattacac agactgggta gatgatcaga gacctgaaaa ctaccgtgag 
gccttgggtg atgttgttgg ggattataat ttcatatgcc ctgccttgga gttcaccaag 
aagttctcag aatggggaaa taatgccttt ttctactatt ttgaacaccg atcctccaaa 
cttccgtggc cagaatggat gggagtgatg catggctatg aaatt 
<210> SEQ ID NO 10 
<211> LENGTH, 375 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 14-2 mutant (A199S/F227A/A328W/Y332G) BChE, 
amino acid sequence for residues 68-442 
<400> SEQUENCE, 10 
Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn 
1 5 10 15 
Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile 
20 25 30 
Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly 
35 40 45 
Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys 
50 55 60 
62 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1125 
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-continued 
Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg 
65 70 75 80 
Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro 
85 90 95 
Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln 
100 105 110 
Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe 
115 120 125 
Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro 
130 135 140 
Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Ala 
145 150 155 160 
Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr 
165 170 175 
Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu 
180 185 190 
Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn 
195 200 205 
Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Ser Val Asn Phe Gly 
210 215 220 
Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu 
225 230 235 240 
Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys 
245 250 255 
Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys 
260 265 270 
Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys 
275 280 285 
Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe 
290 295 300 
His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu 
305 310 315 320 
Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu 
325 330 335 
Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr 
340 345 350 
Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly 
355 360 365 
Val Met His Gly Tyr Glu Ile 
370 375 
<210> SEQ ID NO 11 
<211> LENGTH, 966 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 14-2 mutant (A199S/F227A/A328W/Y332G) BChE 
nucleic acid sequence for residues 117-438 
<400> SEQUENCE, 11 
ggttttcaaa ctggaacatc atctttacat gtttatgatg gcaagtttct ggctcgggtt 60 
gaaagagtta ttgtagtgtc aatgaactat agggtgggtg ccctaggatt cttagctttg 120 
ccaggaaatc ctgaggctcc agggaacatg ggtttatttg atcaacagtt ggctcttcag 180 
tgggttcaaa aaaatatagc agcctttggt ggaaatccta aaagtgtaac tctctttgga 240 
64 
US 9,206,403 Bl 
65 
-continued 
gaaagttccg gagcagcttc agttagcctg catttgcttt ctcctggaag ccattcattg 300 
ttcaccagag ccattctgca aagtggttcc gctaatgctc cttgggcggt aacatctctt 360 
tatgaagcta ggaacagaac gttgaactta gctaaattga ctggttgctc tagagagaat 420 
gagactgaaa taatcaagtg tcttagaaat aaagatcccc aagaaattct tctgaatgaa 480 
gcatttgttg tcccctatgg gactcctttg tcagtaaact ttggtccgac cgtggatggt 540 
gattttctca ctgacatgcc agacatatta cttgaacttg gacaatttaa aaaaacccag 600 
attttggtgg gtgttaataa agatgaaggg acatggtttt tagtcggtgg tgctcctggc 660 
ttcagcaaag ataacaatag tatcataact agaaaagaat ttcaggaagg tttaaaaata 720 
ttttttccag gagtgagtga gtttggaaag gaatccatcc tttttcatta cacagactgg 780 
gtagatgatc agagacctga aaactaccgt gaggccttgg gtgatgttgt tggggattat 840 
aatttcatat gccctgcctt ggagttcacc aagaagttct cagaatgggg aaataatgcc 900 
tttttctact attttgaaca ccgatcctcc aaacttccgt ggccagaatg gatgggagtg 960 
atgcat 966 
<210> SEQ ID NO 12 
<211> LENGTH, 322 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 14-2 (A199S/F227A/A328W/Y332G) a.a residues 
117-438 
<400> SEQUENCE, 12 
Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe 
1 5 10 15 
Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val 
20 25 30 
Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly 
35 40 45 
Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys 
50 55 60 
Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe Gly 
65 70 75 80 
Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly 
85 90 95 
Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Ala Asn 
100 105 110 
Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu 
115 120 125 
Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile 
130 135 140 
Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn Glu 
145 150 155 160 
Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Ser Val Asn Phe Gly Pro 
165 170 175 
Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu Glu 
180 185 190 
Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys Asp 
195 200 205 
Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys Asp 
210 215 220 
66 
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-continued 
Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys Ile 
225 230 235 240 
Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe His 
245 250 255 
Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu Ala 
260 265 270 
Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu Glu 
275 280 285 
Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr Tyr 
290 295 300 
Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly Val 
305 310 315 320 
Met His 
<210> SEQ ID NO 13 
<211> LENGTH, 1722 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 14-3 mutant (A199S/S287G/A328W/Y332G) BChE 
nucleic acid sequence 
<400> SEQUENCE, 13 
gaagatgaca tcataattgc aacaaagaat ggaaaagtca gagggatgaa cttgacagtt 
tttggtggca cggtaacagc ctttcttgga attccctatg cacagccacc tcttggtaga 
cttcgattca aaaagccaca gtctctgacc aagtggtctg atatttggaa tgccacaaaa 
tatgcaaatt cttgctgtca gaacatagat caaagttttc caggcttcca tggatcagag 
atgtggaacc caaacactga cctcagtgaa gactgtttat atctaaatgt atggattcca 
gcacctaaac caaaaaatgc cactgtattg atatggattt atggtggtgg ttttcaaact 
ggaacatcat ctttacatgt ttatgatggc aagtttctgg ctcgggttga aagagttatt 
gtagtgtcaa tgaactatag ggtgggtgcc ctaggattct tagctttgcc aggaaatcct 
gaggctccag ggaacatggg tttatttgat caacagttgg ctcttcagtg ggttcaaaaa 
aatatagcag cctttggtgg aaatcctaaa agtgtaactc tctttggaga aagttccgga 
gcagcttcag ttagcctgca tttgctttct cctggaagcc attcattgtt caccagagcc 
attctgcaaa gtggttcctt taatgctcct tgggcggtaa catctcttta tgaagctagg 
aacagaacgt tgaacttagc taaattgact ggttgctcta gagagaatga gactgaaata 
atcaagtgtc ttagaaataa agatccccaa gaaattcttc tgaatgaagc atttgttgtc 
ccctatggga ctcctttggg tgtaaacttt ggtccgaccg tggatggtga ttttctcact 
gacatgccag acatattact tgaacttgga caatttaaaa aaacccagat tttggtgggt 
gttaataaag atgaagggac atggttttta gtcggtggtg ctcctggctt cagcaaagat 
aacaatagta tcataactag aaaagaattt caggaaggtt taaaaatatt ttttccagga 
gtgagtgagt ttggaaagga atccatcctt tttcattaca cagactgggt agatgatcag 
agacctgaaa actaccgtga ggccttgggt gatgttgttg gggattataa tttcatatgc 
cctgccttgg agttcaccaa gaagttctca gaatggggaa ataatgcctt tttctactat 
tttgaacacc gatcctccaa acttccgtgg ccagaatgga tgggagtgat gcatggctat 
gaaattgaat ttgtctttgg tttacctctg gaaagaagag ataattacac aaaagccgag 
gaaattttga gtagatccat agtgaaacgg tgggcaaatt ttgcaaaata tgggaatcca 
68 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
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69 
-continued 
aatgagactc agaacaatag cacaagctgg cctgtcttca aaagcactga acaaaaatat 
ctaaccttga atacagagtc aacaagaata atgacgaaac tacgtgctca acaatgtcga 
ttctggacat cattttttcc aaaagtcttg gaaatgacag gaaatattga tgaagcagaa 
tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa 
tttaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc 
<210> SEQ ID NO 14 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 14-3 mutant (A199S/S287G/A328W/Y332G) BChE 
amino acid sequence 
<400> SEQUENCE, 14 
Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met 
1 5 10 15 
Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro 
20 25 30 
Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 
35 40 45 
Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser 
50 55 60 
Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu 
65 70 75 80 
Met Trp Asn Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn 
85 90 95 
Val Trp Ile Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp 
100 105 110 
Ile Tyr Gly Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr 
115 120 125 
Asp Gly Lys Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met 
130 135 140 
Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro 
145 150 155 160 
Glu Ala Pro Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln 
165 170 175 
Trp Val Gln Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val 
180 185 190 
Thr Leu Phe Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu 
195 200 205 
Leu Ser Pro Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser 
210 215 220 
Gly Ser Phe Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg 
225 230 235 240 
Asn Arg Thr Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn 
245 250 255 
Glu Thr Glu Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile 
260 265 270 
Leu Leu Asn Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val 
275 280 285 
Asn Phe Gly Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp 
290 295 300 
70 
1500 
1560 
1620 
1680 
1722 
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-continued 
Ile Leu Leu Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly 
305 310 315 320 
Val Asn Lys Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly 
325 330 335 
Phe Ser Lys Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu 
340 345 350 
Gly Leu Lys Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser 
355 360 365 
Ile Leu Phe His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn 
370 375 380 
Tyr Arg Glu Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys 
385 390 395 400 
Pro Ala Leu Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala 
405 410 415 
Phe Phe Tyr Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu 
420 425 430 
Trp Met Gly Val Met His Gly Tyr Glu Ile Glu Phe Val Phe Gly Leu 
435 440 445 
Pro Leu Glu Arg Arg Asp Asn Tyr Thr Lys Ala Glu Glu Ile Leu Ser 
450 455 460 
Arg Ser Ile Val Lys Arg Trp Ala Asn Phe Ala Lys Tyr Gly Asn Pro 
465 470 475 480 
Asn Glu Thr Gln Asn Asn Ser Thr Ser Trp Pro Val Phe Lys Ser Thr 
485 490 495 
Glu Gln Lys Tyr Leu Thr Leu Asn Thr Glu Ser Thr Arg Ile Met Thr 
500 505 510 
Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys 
515 520 525 
Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys 
530 535 540 
Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 
545 550 555 560 
Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 
565 570 
<210> SEQ ID NO 15 
<211> LENGTH, 1125 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 14-3 mutant (A199S/S287G/A328W/Y332G) BChE 
nucleic acid sequence for amino acid residues 68-442 
<400> SEQUENCE, 15 
aacatagatc aaagttttcc aggcttccat ggatcagaga tgtggaaccc aaacactgac 60 
ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc 120 
actgtattga tatggattta tggtggtggt tttcaaactg gaacatcatc tttacatgtt 180 
tatgatggca agtttctggc tcgggttgaa agagttattg tagtgtcaat gaactatagg 240 
gtgggtgccc taggattctt agctttgcca ggaaatcctg aggctccagg gaacatgggt 300 
ttatttgatc aacagttggc tcttcagtgg gttcaaaaaa atatagcagc ctttggtgga 360 
aatcctaaaa gtgtaactct ctttggagaa agttccggag cagcttcagt tagcctgcat 420 
ttgctttctc ctggaagcca ttcattgttc accagagcca ttctgcaaag tggttccttt 480 
aatgctcctt gggcggtaac atctctttat gaagctagga acagaacgtt gaacttagct 540 
72 
US 9,206,403 Bl 
73 
-continued 
aaattgactg gttgctctag agagaatgag actgaaataa tcaagtgtct tagaaataaa 
gatccccaag aaattcttct gaatgaagca tttgttgtcc cctatgggac tcctttgggt 
gtaaactttg gtccgaccgt ggatggtgat tttctcactg acatgccaga catattactt 
gaacttggac aatttaaaaa aacccagatt ttggtgggtg ttaataaaga tgaagggaca 
tggtttttag tcggtggtgc tcctggcttc agcaaagata acaatagtat cataactaga 
aaagaatttc aggaaggttt aaaaatattt tttccaggag tgagtgagtt tggaaaggaa 
tccatccttt ttcattacac agactgggta gatgatcaga gacctgaaaa ctaccgtgag 
gccttgggtg atgttgttgg ggattataat ttcatatgcc ctgccttgga gttcaccaag 
aagttctcag aatggggaaa taatgccttt ttctactatt ttgaacaccg atcctccaaa 
cttccgtggc cagaatggat gggagtgatg catggctatg aaatt 
<210> SEQ ID NO 16 
<211> LENGTH, 375 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 14-3 mutant (A199S/S287G/A328W/Y332G) BChE 
amino acid sequence for residues 68-442 
<400> SEQUENCE, 16 
Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn 
1 5 10 15 
Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile 
20 25 30 
Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly 
35 40 45 
Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys 
50 55 60 
Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg 
65 70 75 80 
Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro 
85 90 95 
Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln 
100 105 110 
Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe 
115 120 125 
Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro 
130 135 140 
Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Phe 
145 150 155 160 
Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr 
165 170 175 
Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu 
180 185 190 
Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn 
195 200 205 
Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly 
210 215 220 
Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu 
225 230 235 240 
Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys 
245 250 255 
74 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1125 
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Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys 
260 265 270 
Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys 
275 280 285 
Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe 
290 295 300 
His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu 
305 310 315 320 
Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu 
325 330 335 
Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr 
340 345 350 
Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly 
355 360 365 
Val Met His Gly Tyr Glu Ile 
370 375 
<210> SEQ ID NO 17 
<211> LENGTH, 966 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 14-3 mutant (A199S/S287G/A328W/Y332G) BChE 
nucleic acid sequence for amino acid residues 117-438 
<400> SEQUENCE, 17 
ggttttcaaa ctggaacatc atctttacat gtttatgatg gcaagtttct ggctcgggtt 60 
gaaagagtta ttgtagtgtc aatgaactat agggtgggtg ccctaggatt cttagctttg 120 
ccaggaaatc ctgaggctcc agggaacatg ggtttatttg atcaacagtt ggctcttcag 180 
tgggttcaaa aaaatatagc agcctttggt ggaaatccta aaagtgtaac tctctttgga 240 
gaaagttccg gagcagcttc agttagcctg catttgcttt ctcctggaag ccattcattg 300 
ttcaccagag ccattctgca aagtggttcc tttaatgctc cttgggcggt aacatctctt 360 
tatgaagcta ggaacagaac gttgaactta gctaaattga ctggttgctc tagagagaat 420 
gagactgaaa taatcaagtg tcttagaaat aaagatcccc aagaaattct tctgaatgaa 480 
gcatttgttg tcccctatgg gactcctttg ggtgtaaact ttggtccgac cgtggatggt 540 
gattttctca ctgacatgcc agacatatta cttgaacttg gacaatttaa aaaaacccag 600 
attttggtgg gtgttaataa agatgaaggg acatggtttt tagtcggtgg tgctcctggc 660 
ttcagcaaag ataacaatag tatcataact agaaaagaat ttcaggaagg tttaaaaata 720 
ttttttccag gagtgagtga gtttggaaag gaatccatcc tttttcatta cacagactgg 780 
gtagatgatc agagacctga aaactaccgt gaggccttgg gtgatgttgt tggggattat 840 
aatttcatat gccctgcctt ggagttcacc aagaagttct cagaatgggg aaataatgcc 900 
tttttctact attttgaaca ccgatcctcc aaacttccgt ggccagaatg gatgggagtg 960 
atgcat 966 
<210> SEQ ID NO 18 
<211> LENGTH, 322 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 14-3 mutant (A199S/S287G/A328W/Y332G) BChE 
amino acid sequence for residues 117-438 
76 
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-continued 
<400> SEQUENCE, 18 
Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe 
1 5 10 15 
Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val 
20 25 30 
Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly 
35 40 45 
Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys 
50 55 60 
Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe Gly 
65 70 75 80 
Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly 
85 90 95 
Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Phe Asn 
100 105 110 
Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu 
115 120 125 
Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile 
130 135 140 
Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn Glu 
145 150 155 160 
Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly Pro 
165 170 175 
Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu Glu 
180 185 190 
Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys Asp 
195 200 205 
Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys Asp 
210 215 220 
Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys Ile 
225 230 235 240 
Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe His 
245 250 255 
Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu Ala 
260 265 270 
Leu Gly Asp Val Val Gly Asp 
275 
Phe Thr Lys Lys Phe Ser 
290 
Phe Glu His Arg Ser 
305 
Met His 
<210> SEQ ID NO 19 
<211> LENGTH, 1722 
<212> TYPE, DNA 
Ser 
310 
Glu 
295 
Lys 
<213> ORGANISM, Artificial 
<220> FEATURE, 
Tyr Asn Phe Ile Cys Pro Ala Leu Glu 
280 285 
Trp Gly Asn Asn Ala Phe Phe Tyr Tyr 
300 
Leu Pro Trp Pro Glu Trp Met Gly Val 
315 320 
<223> OTHER INFORMATION, 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) 
BChE nucleic acid sequence 
<400> SEQUENCE, 19 
gaagatgaca tcataattgc aacaaagaat ggaaaagtca gagggatgaa cttgacagtt 60 
tttggtggca cggtaacagc ctttcttgga attccctatg cacagccacc tcttggtaga 120 
78 
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cttcgattca aaaagccaca gtctctgacc aagtggtctg atatttggaa tgccacaaaa 
tatgcaaatt cttgctgtca gaacatagat caaagttttc caggcttcca tggatcagag 
atgtggaacc caaacactga cctcagtgaa gactgtttat atctaaatgt atggattcca 
gcacctaaac caaaaaatgc cactgtattg atatggattt atggtggtgg ttttcaaact 
ggaacatcat ctttacatgt ttatgatggc aagtttctgg ctcgggttga aagagttatt 
gtagtgtcaa tgaactatag ggtgggtgcc ctaggattct tagctttgcc aggaaatcct 
gaggctccag ggaacatggg tttatttgat caacagttgg ctcttcagtg ggttcaaaaa 
aatatagcag cctttggtgg aaatcctaaa agtgtaactc tctttggaga aagttccgga 
gcagcttcag ttagcctgca tttgctttct cctggaagcc attcattgtt caccagagcc 
attctgcaaa gtggttccgc taatgctcct tgggcggtaa catctcttta tgaagctagg 
aacagaacgt tgaacttagc taaattgact ggttgctcta gagagaatga gactgaaata 
atcaagtgtc ttagaaataa agatccccaa gaaattcttc tgaatgaagc atttgttgtc 
ccctatggga ctcctttggg tgtaaacttt ggtccgaccg tggatggtga ttttctcact 
gacatgccag acatattact tgaacttgga caatttaaaa aaacccagat tttggtgggt 
gttaataaag atgaagggac atggttttta gtcggtggtg ctcctggctt cagcaaagat 
aacaatagta tcataactag aaaagaattt caggaaggtt taaaaatatt ttttccagga 
gtgagtgagt ttggaaagga atccatcctt tttcattaca cagactgggt agatgatcag 
agacctgaaa actaccgtga ggccttgggt gatgttgttg gggattataa tttcatatgc 
cctgccttgg agttcaccaa gaagttctca gaatggggaa ataatgcctt tttctactat 
tttgaacacc gatcctccaa acttccgtgg ccagaatgga tgggagtgat gcatggctat 
gaaattgaat ttgtctttgg tttacctctg gaaagaagag ataattacac aaaagccgag 
gaaattttga gtagatccat agtgaaacgg tgggcaaatt ttgcaaaata tgggaatcca 
aatgagactc agaacaatag cacaagctgg cctgtcttca aaagcactga acaaaaatat 
ctaaccttga atacagagtc aacaagaata atgacgaaac tacgtgctca acaatgtcga 
ttctggacat cattttttcc aaaagtcttg gaaatgacag gaaatattga tgaagcagaa 
tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa 
tttaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc 
<210> SEQ ID NO 20 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) 
BChE amino acid sequence 
<400> SEQUENCE, 20 
Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met 
1 5 10 15 
Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro 
20 25 30 
Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 
35 40 45 
Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser 
50 55 60 
Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu 
65 70 75 80 
80 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1560 
1620 
1680 
1722 
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81 
-continued 
Met Trp Asn Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn 
85 90 95 
Val Trp Ile Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp 
100 105 110 
Ile Tyr Gly Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr 
115 120 125 
Asp Gly Lys Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met 
130 135 140 
Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro 
145 150 155 160 
Glu Ala Pro Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln 
165 170 175 
Trp Val Gln Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val 
180 185 190 
Thr Leu Phe Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu 
195 200 205 
Leu Ser Pro Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser 
210 215 220 
Gly Ser Ala Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg 
225 230 235 240 
Asn Arg Thr Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn 
245 250 255 
Glu Thr Glu Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile 
260 265 270 
Leu Leu Asn Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val 
275 280 285 
Asn Phe Gly Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp 
290 295 300 
Ile Leu Leu Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly 
305 310 315 320 
Val Asn Lys Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly 
325 330 335 
Phe Ser Lys Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu 
340 345 350 
Gly Leu Lys Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser 
355 360 365 
Ile Leu Phe His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn 
370 375 380 
Tyr Arg Glu Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys 
385 390 395 400 
Pro Ala Leu Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala 
405 410 415 
Phe Phe Tyr Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu 
420 425 430 
Trp Met Gly Val Met His Gly Tyr Glu Ile Glu Phe Val Phe Gly Leu 
435 440 445 
Pro Leu Glu Arg Arg Asp Asn Tyr Thr Lys Ala Glu Glu Ile Leu Ser 
450 455 460 
Arg Ser Ile Val Lys Arg Trp Ala Asn Phe Ala Lys Tyr Gly Asn Pro 
465 470 475 480 
Asn Glu Thr Gln Asn Asn Ser Thr Ser Trp Pro Val Phe Lys Ser Thr 
485 490 495 
82 
US 9,206,403 Bl 
83 
-continued 
Glu Gln Lys Tyr Leu Thr Leu Asn Thr Glu Ser Thr Arg Ile Met Thr 
500 505 510 
Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys 
515 520 525 
Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys 
530 535 540 
Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn 
545 550 555 
Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 
565 570 
<210> SEQ ID NO 21 
<211> LENGTH, 1125 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
Gln 
560 
<223> OTHER INFORMATION, 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) 
BChE nucleic acid sequence for amino acid residues 68-442 
<400> SEQUENCE, 21 
aacatagatc aaagttttcc aggcttccat ggatcagaga tgtggaaccc aaacactgac 
ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc 
actgtattga tatggattta tggtggtggt tttcaaactg gaacatcatc tttacatgtt 
tatgatggca agtttctggc tcgggttgaa agagttattg tagtgtcaat gaactatagg 
gtgggtgccc taggattctt agctttgcca ggaaatcctg aggctccagg gaacatgggt 
ttatttgatc aacagttggc tcttcagtgg gttcaaaaaa atatagcagc ctttggtgga 
aatcctaaaa gtgtaactct ctttggagaa agttccggag cagcttcagt tagcctgcat 
ttgctttctc ctggaagcca ttcattgttc accagagcca ttctgcaaag tggttccgct 
aatgctcctt gggcggtaac atctctttat gaagctagga acagaacgtt gaacttagct 
aaattgactg gttgctctag agagaatgag actgaaataa tcaagtgtct tagaaataaa 
gatccccaag aaattcttct gaatgaagca tttgttgtcc cctatgggac tcctttgggt 
gtaaactttg gtccgaccgt ggatggtgat tttctcactg acatgccaga catattactt 
gaacttggac aatttaaaaa aacccagatt ttggtgggtg ttaataaaga tgaagggaca 
tggtttttag tcggtggtgc tcctggcttc agcaaagata acaatagtat cataactaga 
aaagaatttc aggaaggttt aaaaatattt tttccaggag tgagtgagtt tggaaaggaa 
tccatccttt ttcattacac agactgggta gatgatcaga gacctgaaaa ctaccgtgag 
gccttgggtg atgttgttgg ggattataat ttcatatgcc ctgccttgga gttcaccaag 
aagttctcag aatggggaaa taatgccttt ttctactatt ttgaacaccg atcctccaaa 
cttccgtggc cagaatggat gggagtgatg catggctatg aaatt 
<210> SEQ ID NO 22 
<211> LENGTH, 375 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) 
BChE amino acid sequence for residues 68-442 
<400> SEQUENCE, 22 
Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn 
1 5 10 15 
Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile 
84 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1125 
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85 
-continued 
20 25 30 
Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly 
35 40 45 
Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys 
50 55 60 
Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg 
65 70 75 80 
Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro 
85 90 95 
Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln 
100 105 110 
Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe 
115 120 125 
Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro 
130 135 140 
Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Ala 
145 150 155 160 
Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr 
165 170 175 
Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu 
180 185 190 
Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn 
195 200 205 
Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly 
210 215 220 
Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu 
225 230 235 240 
Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys 
245 250 255 
Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys 
260 265 270 
Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys 
275 280 285 
Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe 
290 295 300 
His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu 
305 310 315 320 
Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu 
325 330 335 
Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr 
340 345 350 
Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly 
355 360 365 
Val Met His Gly Tyr Glu Ile 
370 375 
<210> SEQ ID NO 23 
<211> LENGTH, 966 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) 
BChE nucleic acid sequence for amino acid residues 117-438 
<400> SEQUENCE, 23 
86 
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87 
-continued 
ggttttcaaa ctggaacatc atctttacat gtttatgatg gcaagtttct ggctcgggtt 60 
gaaagagtta ttgtagtgtc aatgaactat agggtgggtg ccctaggatt cttagctttg 120 
ccaggaaatc ctgaggctcc agggaacatg ggtttatttg atcaacagtt ggctcttcag 180 
tgggttcaaa aaaatatagc agcctttggt ggaaatccta aaagtgtaac tctctttgga 240 
gaaagttccg gagcagcttc agttagcctg catttgcttt ctcctggaag ccattcattg 300 
ttcaccagag ccattctgca aagtggttcc gctaatgctc cttgggcggt aacatctctt 360 
tatgaagcta ggaacagaac gttgaactta gctaaattga ctggttgctc tagagagaat 420 
gagactgaaa taatcaagtg tcttagaaat aaagatcccc aagaaattct tctgaatgaa 480 
gcatttgttg tcccctatgg gactcctttg ggtgtaaact ttggtccgac cgtggatggt 540 
gattttctca ctgacatgcc agacatatta cttgaacttg gacaatttaa aaaaacccag 600 
attttggtgg gtgttaataa agatgaaggg acatggtttt tagtcggtgg tgctcctggc 660 
ttcagcaaag ataacaatag tatcataact agaaaagaat ttcaggaagg tttaaaaata 720 
ttttttccag gagtgagtga gtttggaaag gaatccatcc tttttcatta cacagactgg 780 
gtagatgatc agagacctga aaactaccgt gaggccttgg gtgatgttgt tggggattat 840 
aatttcatat gccctgcctt ggagttcacc aagaagttct cagaatgggg aaataatgcc 900 
tttttctact attttgaaca ccgatcctcc aaacttccgt ggccagaatg gatgggagtg 960 
atgcat 966 
<210> SEQ ID NO 24 
<211> LENGTH, 322 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 12-7 mutant (A199S/F227A/S287G/A328W/Y332G) 
BChE amino acid sequence for residues 117-438 
<400> SEQUENCE, 24 
Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe 
1 5 10 15 
Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val 
20 25 30 
Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly 
35 40 45 
Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys 
50 55 60 
Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe Gly 
65 70 75 80 
Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly 
85 90 95 
Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Ala Asn 
100 105 110 
Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu 
115 120 125 
Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile 
130 135 140 
Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn Glu 
145 150 155 160 
Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly Pro 
165 170 175 
Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu Glu 
88 
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89 
-continued 
180 185 190 
Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys Asp 
195 200 205 
Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly Phe Ser Lys Asp 
210 215 220 
Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys Ile 
225 230 235 240 
Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe His 
245 250 255 
Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu Ala 
260 265 270 
Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu Glu 
275 280 285 
Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr Tyr 
290 295 300 
Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly Val 
305 310 315 320 
Met His 
<210> SEQ ID NO 25 
<211> LENGTH, 1722 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 12-4 mutant (A199S/F227A/S287G/A328W/E441D) 
BChe nucleic acid sequence 
<400> SEQUENCE, 25 
gaagatgaca tcataattgc aacaaagaat ggaaaagtca gagggatgaa cttgacagtt 
tttggtggca cggtaacagc ctttcttgga attccctatg cacagccacc tcttggtaga 
cttcgattca aaaagccaca gtctctgacc aagtggtctg atatttggaa tgccacaaaa 
tatgcaaatt cttgctgtca gaacatagat caaagttttc caggcttcca tggatcagag 
atgtggaacc caaacactga cctcagtgaa gactgtttat atctaaatgt atggattcca 
gcacctaaac caaaaaatgc cactgtattg atatggattt atggtggtgg ttttcaaact 
ggaacatcat ctttacatgt ttatgatggc aagtttctgg ctcgggttga aagagttatt 
gtagtgtcaa tgaactatag ggtgggtgcc ctaggattct tagctttgcc aggaaatcct 
gaggctccag ggaacatggg tttatttgat caacagttgg ctcttcagtg ggttcaaaaa 
aatatagcag cctttggtgg aaatcctaaa agtgtaactc tctttggaga aagttccgga 
gcagcttcag ttagcctgca tttgctttct cctggaagcc attcattgtt caccagagcc 
attctgcaaa gtggttccgc taatgctcct tgggcggtaa catctcttta tgaagctagg 
aacagaacgt tgaacttagc taaattgact ggttgctcta gagagaatga gactgaaata 
atcaagtgtc ttagaaataa agatccccaa gaaattcttc tgaatgaagc atttgttgtc 
ccctatggga ctcctttggg tgtaaacttt ggtccgaccg tggatggtga ttttctcact 
gacatgccag acatattact tgaacttgga caatttaaaa aaacccagat tttggtgggt 
gttaataaag atgaagggac atggttttta gtctatggtg ctcctggctt cagcaaagat 
aacaatagta tcataactag aaaagaattt caggaaggtt taaaaatatt ttttccagga 
gtgagtgagt ttggaaagga atccatcctt tttcattaca cagactgggt agatgatcag 
agacctgaaa actaccgtga ggccttgggt gatgttgttg gggattataa tttcatatgc 
90 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
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-continued 
cctgccttgg agttcaccaa gaagttctca gaatggggaa ataatgcctt tttctactat 
tttgaacacc gatcctccaa acttccgtgg ccagaatgga tgggagtgat gcatggctat 
gacattgaat ttgtctttgg tttacctctg gaaagaagag ataattacac aaaagccgag 
gaaattttga gtagatccat agtgaaacgg tgggcaaatt ttgcaaaata tgggaatcca 
aatgagactc agaacaatag cacaagctgg cctgtcttca aaagcactga acaaaaatat 
ctaaccttga atacagagtc aacaagaata atgacgaaac tacgtgctca acaatgtcga 
ttctggacat cattttttcc aaaagtcttg gaaatgacag gaaatattga tgaagcagaa 
tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa 
tttaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc 
<210> SEQ ID NO 26 
<211> LENGTH, 574 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 12-4 mutant (A199S/F227A/S287G/A328W/E441D) 
BChe amino acid sequence 
<400> SEQUENCE, 26 
Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met 
1 5 10 15 
Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro 
20 25 30 
Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 
35 40 45 
Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser 
50 55 60 
Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu 
65 70 75 80 
Met Trp Asn Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn 
85 90 95 
Val Trp Ile Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp 
100 105 110 
Ile Tyr Gly Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr 
115 120 125 
Asp Gly Lys Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met 
130 135 140 
Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro 
145 150 155 160 
Glu Ala Pro Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln 
165 170 175 
Trp Val Gln Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val 
180 185 190 
Thr Leu Phe Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu 
195 200 205 
Leu Ser Pro Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser 
210 215 220 
Gly Ser Ala Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg 
225 230 235 240 
Asn Arg Thr Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn 
245 250 255 
Glu Thr Glu Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile 
260 265 270 
92 
1260 
1320 
1380 
1440 
1500 
1560 
1620 
1680 
1722 
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Leu Leu Asn Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val 
275 280 285 
Asn Phe Gly Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp 
290 295 300 
Ile Leu Leu Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly 
305 310 315 320 
Val Asn Lys Asp Glu Gly Thr Trp Phe Leu Val Tyr Gly Ala Pro Gly 
325 330 335 
Phe Ser Lys Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu 
340 345 350 
Gly Leu Lys Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser 
355 360 365 
Ile Leu Phe His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn 
370 375 380 
Tyr Arg Glu Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys 
385 390 395 400 
Pro Ala Leu Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala 
405 410 415 
Phe Phe Tyr Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu 
420 425 430 
Trp Met Gly Val Met His Gly Tyr Asp Ile Glu Phe Val Phe Gly Leu 
435 440 445 
Pro Leu Glu Arg Arg Asp Asn Tyr Thr Lys Ala Glu Glu Ile Leu Ser 
450 455 460 
Arg Ser Ile Val Lys Arg Trp Ala Asn Phe Ala Lys Tyr Gly Asn Pro 
465 470 475 480 
Asn Glu Thr Gln Asn Asn Ser Thr Ser Trp Pro Val Phe Lys Ser Thr 
485 490 495 
Glu Gln Lys Tyr Leu Thr Leu Asn Thr Glu Ser Thr Arg Ile Met Thr 
500 505 510 
Lys Leu Arg Ala Gln Gln Cys Arg Phe Trp Thr Ser Phe Phe Pro Lys 
515 520 525 
Val Leu Glu Met Thr Gly Asn Ile Asp Glu Ala Glu Trp Glu Trp Lys 
530 535 540 
Ala Gly Phe His Arg Trp Asn Asn Tyr Met Met Asp Trp Lys Asn Gln 
545 550 555 560 
Phe Asn Asp Tyr Thr Ser Lys Lys Glu Ser Cys Val Gly Leu 
565 570 
<210> SEQ ID NO 27 
<211> LENGTH, 1125 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 12-4 mutant (A199S/F227A/S287G/A328W/E441D) 
BChE nucleic acid sequence for amino acid residues 68-442 
<400> SEQUENCE, 27 
aacatagatc aaagttttcc aggcttccat ggatcagaga tgtggaaccc aaacactgac 60 
ctcagtgaag actgtttata tctaaatgta tggattccag cacctaaacc aaaaaatgcc 120 
actgtattga tatggattta tggtggtggt tttcaaactg gaacatcatc tttacatgtt 180 
tatgatggca agtttctggc tcgggttgaa agagttattg tagtgtcaat gaactatagg 240 
94 
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gtgggtgccc taggattctt agctttgcca ggaaatcctg aggctccagg gaacatgggt 
ttatttgatc aacagttggc tcttcagtgg gttcaaaaaa atatagcagc ctttggtgga 
aatcctaaaa gtgtaactct ctttggagaa agttccggag cagcttcagt tagcctgcat 
ttgctttctc ctggaagcca ttcattgttc accagagcca ttctgcaaag tggttccgct 
aatgctcctt gggcggtaac atctctttat gaagctagga acagaacgtt gaacttagct 
aaattgactg gttgctctag agagaatgag actgaaataa tcaagtgtct tagaaataaa 
gatccccaag aaattcttct gaatgaagca tttgttgtcc cctatgggac tcctttgggt 
gtaaactttg gtccgaccgt ggatggtgat tttctcactg acatgccaga catattactt 
gaacttggac aatttaaaaa aacccagatt ttggtgggtg ttaataaaga tgaagggaca 
tggtttttag tctatggtgc tcctggcttc agcaaagata acaatagtat cataactaga 
aaagaatttc aggaaggttt aaaaatattt tttccaggag tgagtgagtt tggaaaggaa 
tccatccttt ttcattacac agactgggta gatgatcaga gacctgaaaa ctaccgtgag 
gccttgggtg atgttgttgg ggattataat ttcatatgcc ctgccttgga gttcaccaag 
aagttctcag aatggggaaa taatgccttt ttctactatt ttgaacaccg atcctccaaa 
cttccgtggc cagaatggat gggagtgatg catggctatg acatt 
<210> SEQ ID NO 28 
<211> LENGTH, 375 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 12-4 mutant (A199S/F227A/S287G/A328W/E441D) 
BChE amino acid sequence for residues 68-442 
<400> SEQUENCE, 28 
Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu Met Trp Asn 
1 5 10 15 
Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn Val Trp Ile 
20 25 30 
Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp Ile Tyr Gly 
35 40 45 
Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys 
50 55 60 
Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg 
65 70 75 80 
Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro 
85 90 95 
Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln 
100 105 110 
Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe 
115 120 125 
Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro 
130 135 140 
Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Ala 
145 150 155 160 
Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr 
165 170 175 
Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu 
180 185 190 
96 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1125 
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-continued 
Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn 
195 200 205 
Glu Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly 
210 215 220 
Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu 
225 230 235 240 
Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys 
245 250 255 
Asp Glu Gly Thr Trp Phe Leu Val Tyr Gly Ala Pro Gly Phe Ser Lys 
260 265 270 
Asp Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys 
275 280 285 
Ile Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe 
290 295 300 
His Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu 
305 310 315 320 
Ala Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu 
325 330 335 
Glu Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr 
340 345 350 
Tyr Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly 
355 360 365 
Val Met His Gly Tyr Asp Ile 
370 375 
<210> SEQ ID NO 29 
<211> LENGTH, 975 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 12-4 mutant (A199S/F227A/S287G/A328W/E441D) 
BChE nucleic acid sequence for amino acid residues 117-441 
<400> SEQUENCE, 29 
ggttttcaaa ctggaacatc atctttacat gtttatgatg gcaagtttct ggctcgggtt 60 
gaaagagtta ttgtagtgtc aatgaactat agggtgggtg ccctaggatt cttagctttg 120 
ccaggaaatc ctgaggctcc agggaacatg ggtttatttg atcaacagtt ggctcttcag 180 
tgggttcaaa aaaatatagc agcctttggt ggaaatccta aaagtgtaac tctctttgga 240 
gaaagttccg gagcagcttc agttagcctg catttgcttt ctcctggaag ccattcattg 300 
ttcaccagag ccattctgca aagtggttcc gctaatgctc cttgggcggt aacatctctt 360 
tatgaagcta ggaacagaac gttgaactta gctaaattga ctggttgctc tagagagaat 420 
gagactgaaa taatcaagtg tcttagaaat aaagatcccc aagaaattct tctgaatgaa 480 
gcatttgttg tcccctatgg gactcctttg ggtgtaaact ttggtccgac cgtggatggt 540 
gattttctca ctgacatgcc agacatatta cttgaacttg gacaatttaa aaaaacccag 600 
attttggtgg gtgttaataa agatgaaggg acatggtttt tagtctatgg tgctcctggc 660 
ttcagcaaag ataacaatag tatcataact agaaaagaat ttcaggaagg tttaaaaata 720 
ttttttccag gagtgagtga gtttggaaag gaatccatcc tttttcatta cacagactgg 780 
gtagatgatc agagacctga aaactaccgt gaggccttgg gtgatgttgt tggggattat 840 
aatttcatat gccctgcctt ggagttcacc aagaagttct cagaatgggg aaataatgcc 900 
tttttctact attttgaaca ccgatcctcc aaacttccgt ggccagaatg gatgggagtg 960 
98 
US 9,206,403 Bl 
99 
-continued 
atgcatggct atgac 
<210> SEQ ID NO 30 
<211> LENGTH, 325 
<212> TYPE, PRT 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, 12-4 mutant (A199S/F227A/S287G/A328W/E441D) 
BChE amino acid sequence for residues 117-441 
<400> SEQUENCE, 30 
Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr Asp Gly Lys Phe 
1 5 10 15 
Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met Asn Tyr Arg Val 
20 25 30 
Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro Glu Ala Pro Gly 
35 40 45 
Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln Trp Val Gln Lys 
50 55 60 
Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val Thr Leu Phe Gly 
65 70 75 80 
Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu Leu Ser Pro Gly 
85 90 95 
Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser Gly Ser Ala Asn 
100 105 110 
Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg Asn Arg Thr Leu 
115 120 125 
Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn Glu Thr Glu Ile 
130 135 140 
Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile Leu Leu Asn Glu 
145 150 155 160 
Ala Phe Val Val Pro Tyr Gly Thr Pro Leu Gly Val Asn Phe Gly Pro 
165 170 175 
Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp Ile Leu Leu Glu 
180 185 190 
Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly Val Asn Lys Asp 
195 200 205 
Glu Gly Thr Trp Phe Leu Val Tyr Gly Ala Pro Gly Phe Ser Lys Asp 
210 215 220 
Asn Asn Ser Ile Ile Thr Arg Lys Glu Phe Gln Glu Gly Leu Lys Ile 
225 230 235 240 
Phe Phe Pro Gly Val Ser Glu Phe Gly Lys Glu Ser Ile Leu Phe His 
245 250 255 
Tyr Thr Asp Trp Val Asp Asp Gln Arg Pro Glu Asn Tyr Arg Glu Ala 
260 265 270 
Leu Gly Asp Val Val Gly Asp Tyr Asn Phe Ile Cys Pro Ala Leu Glu 
275 280 285 
Phe Thr Lys Lys Phe Ser Glu Trp Gly Asn Asn Ala Phe Phe Tyr Tyr 
290 295 300 
Phe Glu His Arg Ser Ser Lys Leu Pro Trp Pro Glu Trp Met Gly Val 
305 310 315 320 
Met His Gly Tyr Asp 
325 
100 
975 
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What is claimed is: 
1. A method for generating butyryl cholinesterase mutants 
said method comprising: ' 
generating an initial structure of the transition state struc-
ture for the rate determining step of the cocaine hydroly-
sis catalyzed by a possible butyrylcholinesterase 
mutant; 
102 
expressing a protein encoded by mutant nucleic acid 
sequence to produce mutant butyrylcholinesterase, and 
performing a catalytic activity assay on the mutant butyryl-
cholinesterase. 
4. The method of claim 1, wherein said hybrid quantum 
mechanical/molecular mechanical geometry optimization, 
calculating the hydrogen binding energies, and evaluating the 
energy barrier are conducted only if the hydrogen binding performing a sufficiently long time molecular dynamics 
simulation on the transition state structure in water to 
have a stable molecular dynamic trajectory; 
analyzing the molecular dynamic trajectory and estimating 
the hydrogen binding energies between the carbonyl 
?xygen of the (-)-cocaine benzoyl ester and the oxyan-
lon hole of the possible butyrylcholinesterase mutant· 
10 
energies between the carbonyl oxygen of the (-)-cocaine 
benzoyl ester and the possible butyrylcholinesterase mutant, 
i~ the transition state, are stronger than known butyrylcho-
lmesterase mutants against (-)-cocaine. 
5. The method of claim 1, further comprising determining 
the rate limiting step in the hydrolysis of (-)-cocaine by the 
possible butyrylcholinesterase mutant by conducting the 
molecular dynamic simulations and quantum mechanical/ 
molecular mechanical calculations relating to the transition 
states for other reaction steps between (-)-cocaine by the 
if the hydrogen binding energies between the carbon~! 15 
oxygen of the (-)-cocaine benzoyl ester and the possible 
butyrylcholinesterase mutant, in the transition state are 
stronger than the hydrogen binding energies betwee~ the 
carbonyl oxygen of the (-)-cocaine benzoyl ester and 
wild type butyrylcholinesterase: 20 possible butyrylcholinesterase mutant, and calculating 
respective energy barriers, thereby establishing which of the 
reaction steps is rate determining one. 
calculating the hydrogen binding energies, 
evaluating the energy barrier, and 
generating butyrylcholinesterase mutant. 
2. The method of claim 1, wherein said generating an initial 
structure of the transition state structure is based on reaction 25 
coordinate calculations for the wild type butyrylcholinest-
erase. 
3 .. The method of claim 1, wherein said generating butyryl-
cholmesterase mutant comprising: 
performing site directed mutagenesis on a nucleic acid 30 
sequence encoding wild type butyrylcholinesterase, to 
generate the mutant butyrylcholinesterase nucleic acid 
sequence; 
6. ~he method of claim 1, wherein if the hydrogen binding 
energ1es between the carbonyl oxygen of the (-)-cocaine 
benzoyl ester and the possible butyrylcholinesterase mutant 
in the.transition state, are stronger than the hydrogen bindin~ 
energ1es between the carbonyl oxygen of the (-)-cocaine 
benz?yl ester ~nd wild type butyrylcholinesterase furtherper-
formmg hybnd quantum mechanical/molecular mechanical 
g.eometry optimization to refine the molecular dynamics-
Simul~ted structure prior to calculating the hydrogen binding 
energ1es. 
* * * * * 
